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Chapter 1 
Introduction: 
Molecular markers of melanocyte tumor progression 
Modified from: Lab. Invest., 1994, in press. 

INTRODUCTION 
The incidence of human cutaneous melanoma, a malignancy of melanocytes, increased more 
than that of any other cancer over the last decades (1). A primary melanoma in situ or an early 
invasive melanoma (thickness < 1 mm) can be surgically removed with ample margins resulting 
in a cure of 99% (2). However, prospects are far worse for thick or advanced melanomas (3). Up 
to now, the most reliable diagnostic progression marker is the tumor thickness measured according 
to Breslow (4), and next to that, the level of invasion (Clark level)(5). A high number of 
dysplastic nevi or atypical moles can be considered a risk factor for both familial and sporadic 
melanoma. An unusual high amount of dysplastic nevi was first described as the B.-K.-syndrome, 
now referred to as dysplastic nevus syndrome (DNS) or familial atypical multiple mole-melanoma 
syndrome (FAMMM), a predisposition for melanoma in inheriting families (6). Other independent 
risk factors have been described, like severe sunburn in childhood; they are discussed elsewhere 
(7,8). 
Melanocyte tumor progression evolves through several stages, as indicated by clinical, 
histopathologic and immunohistochemical characteristics. The steps in melanocyte progression 
were defined by Clark et al. (9) and Herlyn et al. (10), and are schematically depicted in Figure 
1. 
Figure 1: 
Common acquired melanocyte nevus 
; 
Melanocyte nevus with structural atypia 
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Atypical or dysplastic nevus (DN) with cytological 
and architectural atypia 
I 
Primary Melanoma (PM), radial growth phase (RGP) 
1 
Primary Melanoma, vertical growth phase (VGP) 
I 
Melanoma Metastasis (MM) 
For diagnostic and prognostic purposes, it would be very helpful to have appropriate markers 
that distinguish these stages since for example the radial growth phase seems incapable of 
metastasis which makes it a pivotal lesion in melanocyte tumor biology (11). Extensive research 
has been performed to search for progression markers, and to determine biological differences 
between the cells from different stages in order to gain more insight in the tumor biology of 
melanoma. Progression markers can be defined as molecules with a preferential expression for one 
or a few stages of melanocyte progression. Early markers are mostly expressed in the benign 
stages and can also be named inverse progression markers. Late progression markers show 
increased expression in the advanced stages of progression. 
Many genes or gene products have been identified which are differentially expressed during 
progression. This review deals with various aspects of this progression in terms of changes in the 
tumor genome, the expression of oncogenes, tumor suppressor genes, progression markers, and 
genes, which are all potentially implied in progression and metastasis. 
In order to identify these changes, several strategies exist: 
1. Genomic instability. In melanomas as in other cancers, next to many non-specific changes, 
reflecting genomic instability, a number of consistent chromosomal aberrations occurs. The 
identification of these changes together with linkage analysis in families with a predisposition for 
melanoma led to the isolation of a potential suppressor gene on chromosome 9 (12-15). 
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2. Growth faeton, growth factor receptors, oncogenes, and tumor suppressor genes. 
Several methods led to the isolation of many oncogenes, often encoding growth factors and growth 
factor receptors. The involvement of oncogenes and tumor suppressor genes in melanocyte 
progression is discussed below. 
3. Candidate genes. In terms of the search for possible important genes, candidates can be found 
among genes involved in processes that are necessary for tumor cells to escape controlling signals, 
acquire invasive and metastatic properties, such as genes involved in adhesion, cellular 
communication and signaling, matrix degradation, and motility. Among these genes oncogenes 
and tumor suppressor genes are also plausible candidates. 
4. Progression markers identified by antibodies. Since the introduction of the hybridoma technique 
(16), many monoclonal antibodies (Mabs) have been raised recognizing a single epitope. 
Antibodies with a preferential expression in one or more subsequent stages could point into the 
direction of possible important genes. Whenever the function of these molecules is known, it is 
discussed in the corresponding section. 
5. Differentially expressed clones as identified by differential or subtractive cloning procedures. 
Gene expression is compared of low- versus highly metastatic melanoma cell lines, xenografts or 
patient lesions representing benign and malignant stages, which will also be discussed in Chapter 
2, 4, and 5. 
The first, fourth and fifth approaches represent more direct methods to isolate potentially 
involved genes. The results of all approaches which are partly overlapping, are described below in 
relation to melanocyte tumor progression. 
1. GENOMIC INSTABILITY. 
During human melanocyte tumor progression a number of chromosomal abnormalities occur, 
together with increasing aneuploidy (17) as reviewed elsewhere (18-21). Chromosomes that are 
often involved include chromosome 1, 3, 6, 7, 9, 10, 11, and 19. There are several studies 
providing evidence that among the earliest changes is the loss of part of chromosome 9. Dracopoli 
et al. showed that a common loss of heterozygosity (LOH) was detected in all six metastases from 
one patient on chromosome 9p (22). Pedersen and Wang (23) also examined more tumors of the 
same patient and proposed that chromosome 1 and 9 were involved in the onset of tumorigenicity, 
whereas chromosome 2, 3, and 6 were associated with progression. Parmiter et al. described a 
translocation of chromosome 9 to 10 in 2 out of 10 dysplastic nevi (DN) (24). Loss of 
chromosome 10 was also observed in primary melanoma and metastases (24). A deletion on the 
short arm of chromosome 9 in DN was also detected by Cowan et al., which was the only 
aberration in common with primary melanoma (25). Three groups independently identified a 
region on chromosome 9 (9p21) which might comprise a susceptibility gene leading to a 
predisposition for melanoma (12-15). When studying the FAMMM syndrome a correlation with a 
region on chromosome 1 (lp36) had also been made (26,27), but could not be confirmed by 
others (28-31), indicating that more genes may be involved in this phenomenon. Recently, LOH at 
llq23 was detected in 67% of 46 cases of sporadic melanoma (32). Mutations at this locus were 
associated with younger age at presentation. Preliminary information of the clinical outcome in 
relation to chromosome 7 and 11 was provided by Trent (19) revealing that abnormalities 
associated with these chromosomes resulted in a shorter survival time. Remarkably, elevated 
expression of epidermal growth factor receptor (EGFR), which we found to be associated with 
progression in a human melanoma model system (33) correlated with the number of copies of 
chromosome 7 (34). Frequently, a loss of part of chromosome 6 was also observed (6q 15-21) 
(35). Microcell chromosome 6 hybrids were introduced into human melanoma cell lines leading to 
a significant alteration of phenotype, including loss of tumorigenicity (36). LOH on 6q was 
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detected in 40 % of 53 patients (37), suggesting the presence of a tumor suppressor gene. 
Suppression of tumorigenicity was also observed by Church et al. (38) after transfection of 
manganese superoxide dismutase which is localized on 6q25 and had the same effect on this cell 
line. 
Although abnormalities concerning chromosome 1, 6, and 7 are most common in melanoma 
(18,39,40), chromosome 1 is probably involved in tumor progression in general, since 
abnormalities have been described for a number of cancers (40-42). 
2. GROWTH FACTORS, GROWTH FACTOR RECEPTORS, ONCOGENES, AND 
TUMOR SUPPRESSOR GENES 
Growth factor (GF) production and dependance change during melanocyte tumor 
progression(43). This topic has been extensively reviewed (44-49) and will not be discussed here 
in detail. The changes in growth requirements of melanocyte cells from different stages already 
reflect progression. Whereas normal melanocytes are grown mostly in the presence of several 
growth factors and 12-0-tetradecanoylphorbol-13-acetate (TPA), cultured cells derived from nevi 
show a reduced need for TPA and basic fibroblast growth factor (bFGF) (50), early melanoma 
cell lines require only insulin or insulin-like growth factor I (IGF-I), whereas advanced melanoma 
cell lines and those derived from melanoma metastases grow autonomously. Congenital nevus cells 
are also less dependent on bFGF (51). Since normal adult melanocytes in vivo hardly ever divide, 
caution has to be taken when using melanocytes in culture. TPA was shown to elevate the level of 
certain progression markers (A1.43 and AIO.33), to enhance proliferation rate, and to decrease 
the expression of an early progression marker (K1.2) (52). Culturing in serum-free AIM-V 
(without TPA) medium resulted in increase of differentiation in terms of tyrosinase activity and 
melanin content (53). 
One of the most potent mitogens for melanocytes and an intracellular autocrine GF for 
melanoma cells is basic fibroblast growth factor (bFGF). Although neutralizing antibodies 
directed against bFGF had no effect on the growth of melanoma cells (54), antisense bFGF 
oligonucleotides did inhibit growth (55). However, murine melanocytes transfected with bFGF 
were non-tumorigenic in nude mice (56). Antisense FGFR-constructs led to inhibition of growth, 
extensive dendrite formation and disruption of the cell-cell contact (57). 
A fibroblast-derived inhibitory factor was isolated that appeared to be identical to interleukin-6 
(IL-6) (58,59). During melanocyte tumor progression advanced primary and metastatic 
melanomas acquired a multicytokine resistance to ILI, tumor necrosis factor α (TNFa), and 
oncostatin M (60) as well as IL-6. Neutralizing anti-IL-6 antibodies had no effect on melanoma 
cells whereas antisense IL-6 did, leading to the suggestion of the existence of a private autocrine 
loop by Kerbel and coworkers (59,61). 
EGFR has been described as a progression marker, discriminating between DN and RGP versus 
VGP and MM (44,62) or elevated in PM and MM as compared to common acquired nevi, leaving 
DN in an intermediate position (33). An EGFR analog also appeared to be important in the 
development of ned i tar y melanoma in the fish Xiphophorus. When crossbreeding Xiphophorus 
helleri χ X. maculatus to X. helleri, 50% of the offspring is hyperpigmentated, often leading to 
melanomas. A combination of genetic and molecular studies revealed the presence of both an 
oncogene and a suppressor gene. The oncogenic Tu locus (63) codes for Xmrk, an EGFR analog. 
Expression of Xmrk correlated with the degree of malignancy (64). Suppression of this locus was 
achieved by the regulatory gene R. When this locus was deleted in hybrids, and Tu was present, 
the animals developed melanoma. Tu itself emerged from a non-homologous recombination of an 
X-chromosomal gene (proto-oncogene) and the D-locus, by which event the Xmrk was present in 
an extra copy coupled to an accidentally acquired promotor (65). 
Transfections of several oncogenes into murine melanocytes only led to tumorigenicity in the 
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case of Ha-ras, myc and neu oncogenes (56). Ras mutations were not detected very often in 
patient lesions (5-13%)(66-68), however, ras mutations could be detected in 24% of human 
melanoma cell lines, N-ras being 10 times more frequently mutated than Ha-ras (67). However, 
transfection of ras oncogenes into melanocytes only resulted in a partial transformation. Retroviral 
transfection with a construct carrying v-Ha-ras led to a complete transformation accompanied by 
the loss of differentiation characteristics and increased expression of certain progression markers 
(69) thus providing a useful model system for melanocyte transformation. 
The NF-1 locus, which is altered in patients with neurofibromatosis, and which encodes a 
potential p21""-regulating GTPase activating protein, was deleted in 1/8 melanoma cell lines (70). 
In 5/9 cell lines an abnormal low level of neurofibromin was detected, however, without any 
deregulation of the amounts of GTP incorporated by p21~ (71). 
The non receptor tyrosine kinase c-yes showed a 5-10 fold elevated kinase activity in human 
melanoma cell lines as compared to melanocytes (72), due to changed protein levels. Since a 
heavily phosphorylated substrate was only detected in the case of melanoma cell lines, a disturbed 
c-yes signaling pathway might play a role in the transformation of human melanocytes. Receptor 
tyrosine kinases (RTKs) which are involved in cellular signaling are also implied in melanocyte 
tumor progression. Loss of expression of c-kit, a receptor tyrosine kinase which maps to the white 
spotting locus W in mice, was reported during progression (73-75). Cell lines made from W ¥ 
mice carrying a point mutation in the catalytic domain of c-kit appeared to be tumorigenic after 
survival through a crisis in tissue culture (76). Transgenic animals carrying the ret-oncogene, a 
kit-related RTK showed severe melanosis and frequently developed melanomas (77). Crossing 
this strain of mice to mice carrying a mutation in c-kit (WW) compensates the defect, however, 
melanomas developed later on (78). Transgenic animals carrying SV40 oncogenic sequences 
coupled to the tyrosinase promotor (the main enzyme in the formation of melanin) were 
hypopigmented and also predisposed to melanomas (79,80). All melanocyte cultures of these 
transgenes led to cell lines changing in an orderly progression toward malignancy (81). 
Next to the study of chromosomal abnormalities, indications for suppressor genes for melanoma 
were derived from fusion experiments. Hybrids of mouse melanoma B16F10 cells with 
melanocytes from 'albino' or 'brown' lines led to hybrids with black pigment and suppression or 
reduction of tumorigenicity (82). However, hybrids of murine metastatic and non-metastatic 
K1735 melanoma cell lines (83) showed varying metastatic potential. The fact that in the latter 
case the hybrids were derived from two melanoma cell lines only instead of from a combination of 
melanocytes and melanoma cells, might explain the prevalence of the metastatic phenotype. 
p53, a potential suppressor gene, that can act as a oncogene when activated, was originally 
reported to be overexpressed and mutated in a large percentage of melanomas (85%)(84). 
Monoclonal antibodies discriminating between the mutant and wild type form were unfortunately 
not reliable in immunostainings, leading to false positives due to recognition of a denatured wild 
type form of p53 or stabilizing effects of other mutations (85-87). False negatives were also 
described (85). A high expression of p53 detected by the antibody recognizing the mutant form 
was described by Akslen (88). Immunoprecipitation using melanoma cell lines led to much lower 
percentages of p53 mutations: 1/9 cell lines (88), 1/11 cell lines (89) or 4/13 cell lines (90). 
Staining with several distinct antibodies or staining patterns of nucleus or cytoplasm, which may 
be informative since p53 acts as a transcription factor in the nucleus, did not predict mutations 
correctly (90). Immunostaining of patient lesions, not revealing whether wild type or mutant form 
is detected, showed p53 in a low percentage of nevocellular nevi (NN), DN, and PM, but in 70% 
of the cases in MM, however, often less than 20% of the cells within a lesion were stained (91). 
Another study using a polyclonal antibody also detected the highest amount of staining cells within 
MM (5%)(92), suggesting that p53 activation is a late event. This is confirmed by a lack of 
correlation between metastatic behavior of human melanoma cells and p53 mutations (89). 
However, a strong correlation with malignancy was detected by McGregor et al (93) showing p53 
protein in 63% of tumor specimens and no or a weak staining in NN and DN. Although it is 
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unclear whether p53 protein is mutated, its expression is mainly detected in the later stages of 
melanocyte tumor progression. 
3. CANDIDATE GENES 
In order to become a tumor cell and to be able to metastasize a melanocyte cell has to escape 
from controlling signals from its environment, acquire capacities to invade, among which an 
increased motility, the capability to break down the extracellular matrix (ECM), invade through 
the basal membrane and a concomitant flexibility (94) and adaptation of the cytoskeleton. It has to 
survive in the blood stream, escape from the immune system arrest at a secondary site, processes 
in which blood platelets are thought to be important (95), invade through the basal membrane and 
finally, grow at a secondary site. All molecules involved in these processes are possible and 
interesting candidates. However, melanoma cells with different metastatic potential do not need to 
differ in all aspects mentioned (96). Although expression of certain adhesion molecules is 
mandatory for arrest in the vasculature and outgrowth at a secondary site, expression may be 
transitory and thus escape our observation. The initial events lie within the tumor cells themselves. 
For instance, changes in processes like DNA repair can lead to a less stable cell. The increased 
risk for melanoma in Xeroderma pigmentosum patients obviously shows that altered DNA repair 
can increase the risk for melanoma. 
Cellular adhesion molecules 
Expression of MUC18, a neural cellular adhesion molecule (NCAM) related molecule, was 
detected in a smaller percentage of nevi than of melanomas (97) and expression in melanomas 
correlated with tumor thickness and a poor prognosis (98). Vascular cellular adhesion molecule 
(VCAM), normally present on cells of the vascular endothelium, and the receptor for a401 
integrin (99), was present on both benign and malignant lesions (100) but downregulated during 
progression especially in thick PMs (101). A lung-metastasizing B16 variant bound to lung 
endothelial cellular adhesion molecule (Lu-ECAM-1) in a higher percentage than the lower-
metastatic counterpart. Passive or active immunization of these mice with (anti-)Lu-ECAMl 
resulted in a reduction of metastasis as measured by the formation of lung colonies (102). When 
comparing a metastatic and non-metastatic murine melanoma cell line a lower expression of 
NCAM was detected in the metastatic counterpart. However, the protein could be found in three 
forms instead of two (103). In a very small study, expression was not found in DN but present in 
some PMs (104). 
A 89 kD glycoprotein, recognized by monoclonal antibody P3.S8, and postulated as a 
progression marker for human melanoma (105), appeared to be identical with intercellular 
adhesion molecule 1 (ICAM-1) (106). Expression was detected on advanced melanomas but not on 
benign lesions. Monoclonal antibody C1203.4 also recognized ICAM-1 and was found in a higher 
percentage on metastatic melanomas than on primary melanomas, and showed a markedly 
decreased expression on benign lesions. In stage I patients a significant correlation with the 
clinical course of disease was found (107). Elevated serum levels of ICAM-1 were detected in all 
patients harboring melanoma (108,109). Expression in stage II and III patients also showed an 
inverse correlation with survival (108,109). A study using xenografts in nude mice showed that 
indeed the tumor in this system was the source of the elevated serum levels (110), although 
reduced when compared to the levels of ICAM-1 shed into the medium of cultured melanoma cell 
lines. ICAM-1 expression on the membrane and of the soluble form can be modulated by retinoic 
acid (RA) and several cytokines (110-113). Soluble ICAM-1 isolated from patients inhibited lysis 
of melanoma cells by allogeneic natural killer (NK) cells in a dose-dependant way (114). Anti-
ICAM-1 antibodies partially inhibited lysis of melanoma cells by NK cells, lymphokine activated 
killer cells (LAKs) and to a greater extent, autologous tumor infiltrated lymphocytes (TILs) (114). 
In contrast, expression on selected cytotoxic Τ lymphocytes (CTLs) from melanoma with highest 
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susceptibility to lysis showed highest ICAM-1 expression (115). A more recent study described 
expression of both ICAM-1 and MUC18 on both benign and malignant cells (101), suggesting that 
differences in antigen expression might be explained by differences in sensitivity of staining 
techniques and avidity of the antibodies, from which may be concluded that expression of these 
antigens comprise quantitative rather than qualitative differences. 
Integrine 
Integrine form a family of heterodimers consisting of an α and a β chain, mediating cell-cell 
contacts and attachment to extracellular matrix components. Although integrin expression on 
melanocytes is heterogeneous, integrin expression on melanoma cells is augmented (αϊ, α2, α3, 
а4, а5, αϊ, αν, and ß3)(l 16-119). Culturing melanocytes would introduce the classic fibronectin 
and vitronectin receptors: aSIH (very late antigen 5 (VLAS)) and а ВЗ respectively (116). In 
melanoma cell lines а ВЗ has most often been described as associated with progression (120-125). 
Also o2ßl (VLA2)(117,120,126,127), а4В1 (VLA4)(117,124,125) and абВІ (VLA6)(120,126) 
have been described in this way. Vink et al. (120) reported the acquisition of a2ßl integrin, next 
to either абВІ, when metastasizing to the lungs and other tissues, or а ВЗ when metastasizing to 
the lungs only. In В16 variants, аІІЬВЗ (128,129) was also reported to be elevated in higher 
metastatic cells. Synthetic peptides comprising adhesion sequences of integrins (RGD or YIGSR) 
were shown to inhibit experimental metastasis (130-132). 
However, when looking at tissue sections instead of cell lines, аб and al sububits were 
reported to be downmodulated (133-136), whereas а ВЗ was present in advanced melanomas and 
melanoma metastases (134,137). McGregor et al. also described B3 as present in most 
melanomas, but absent in normal skin, melanocytes, common or dysplastic nevi (138). Moretti et 
al. reported expression of B3 in thick PMs and MM (136). VLA3 expression (аЗВІ) was reported 
to be correlated with the degree of invasiveness in primary melanomas (139). An increase in the 
expression of VLA4 was also reported during progression (134-136), next to the emergence of 
VLA5 (134,135). Changes in al, cr4, and аб correlated with tumor thickness, but only the 
increase in the expression of a4 and the decrease of аб correlated with development of metastases 
(135). 
Recently, a second function was described for integrins as signaling intermediates. Signaling 
through integrins was described by Hynes (140), Schwartz (141), and Mortarini and Anichini 
(119). Fibronectin (FN) and an RGD-containing fragment provided a mitogenic signal when 
VLA5 was present (142). Stimulation of а ВЗ (121) or o5Bl (143) by antibodies led to higher 
levels of 72 Ш collagenase and concomitant increased invasive potential. The distribution of 
integrins in melanoma cell lines and patient lesions is summarized in Table 1. 
Adhesion-related molecules 
Melanoma cells contain high amounts of gangliosides (144,145) which are thought to be 
implicated in several processes like the regulation of proliferation, communication, adhesion and 
immune reaction (146-149). An enhanced expression of disialogangliosides (GD2.GD3) was 
detected on melanoma cells or transformed melanocytes as compared to normal melanocytes 
(69,150-152). GD2 expression was mainly detected in advanced PM and melanoma metastases 
(153). Detection of gangliosides using monoclonal antibodies was dependent on the total 
ganglioside composition of the cell (154) and cross reaction with other gangliosides (145). In 
melanomas, GD3 is detected frequently. However, also in nevi GD3 was detected (145). Two 
monoclonale raised against melanoma cells recognizing GD3 showed a gradual increase in 
subsequent steps of progression (62). When using a dynamic model instead of a static one, in 
which a tumor suspension is allowed to flow over a glass plate that is coated with FN, lectins or 
glycosphingolipids, adhesion mediated by glycosphingolipids is predominant over lectin- or 
integrin-mediated adhesion, which also shows the testing system to be very important (155). 
Tenascin, a glycoprotein of the ECM, expressed during embryogenesis and in wound healing 
16 
Table 1: Progression-associated integrins 
Cultured melanoma cell lines 
+avß3 
+tt2ßl 
+r*4ßl 
+or6ßl 
+allbß3 
+a7ßl 
(120-125) 
(117.12M2e.127) 
(117.124,125) 
(120.126) 
(128,129) 
am 
Patient lesions 
+avß3 
+a2ßl 
+a4ßl 
-a6ßl 
-a6ß4 
-alßl 
+allbß3 
+a3ßl 
+ a5ßl 
+o7ßl 
(134.136.137) 
(219) 
(134-136) 
(133.136) 
(134) 
(135) 
(13«) 
(139) 
(134.135) 
(117) 
Both in melanoma cell linea and patient lesiona integiin aubunita or types of integrins are summarized that are either 
upregulated as indicated by a + , or downregulated as indicated by a -. 
and tumorigenesis, was present in elevated levels in serum of patients with advanced melanomas, 
the differences being too small however, to be useful for diagnostic purposes (156). Tenascin was 
also detected in benign lesions but an increased expression was found to correlate with greater 
dermal invasiveness (157). 
Proteinases 
Matrix degradation can be achieved by cells using several proteinase systems and has been 
reviewed by Cottam and Rees (158), Monsky and Chen (159), and Mignatti and Rifkin (160). 
Both components of the plasminogen activation system and metalloproteinases (MMPs) have been 
described in relation to invasive and metastatic potential. The occurrence of natural inhibitors 
(plasminogen activator inhibitors (PAIs), and tissue inhibitors of metalloproteinases (TIMPs)) 
provide a versatile control system in adhesion and degradation. 
A synthetic part of laminin could stimulate tissue type plasminogen activator (tPA) activation 
only in highly metastatic B16F10 melanoma cells, whereas no effect was observed on lowly 
metastatic B16F1 cells (161). Moreover, stimulation by this peptide also led to an increase in lung 
colonization of B16F10 (162). B16F1 cells transfected with a preproform of urokinase (uPA) also 
showed increased ability to metastasize (163). Conversely, transfection using antisense uPA led to 
a decrease in lung colonization (163). Remarkably, uPA was mainly detected on amelanotic 
tumors (163). Quax et al. reported a high expression of uPA and PAI-1 in highly metastatic 
human melanoma cell lines only. (164). In patient lesions, uPA, PAI-1, PAI-2, and uPAR 
emerged late in tumor progression. uPAR expression was restricted to tumor cells, whereas uPA 
could be detected in stromal and tumor cells at the invasive front (165). 
Matrix degradation is mostly due to combined activity of the PA system and MMPs. In M24met 
cells, which are highly invasive, uPA dependent degradation of matrix glycoproteins preceded 
MMP-dependent collagenolysis (166). In the same cell line and two other highly metastatic human 
melanoma cell lines a thousandfold elevation of the expression of tissue factor, a major cellular 
initiator of plasma coagulation protease cascades was reported. Antibodies to this factor reduced 
the number of cells held in the lung vasculature and the growth of pulmonary metastases (167). 
Injection of (168) or transfection with inhibitor TIMP-1 in B16F10 cells (169,170) resulted in a 
decreased invasive ability. Only under slightly acidic conditions, B16 sublines secreted gelatinase 
into the medium, proportionally to their metastatic potential, indicating the importance of the 
microenvironment of a tumor (171). Likewise, levels of cathepsins (lysosomal proteinases) have 
been reported to be elevated in higher metastatic murine melanoma cell lines (172-175). Cathepsin 
D could be detected in malignant melanoma, but not on benign nevi (176). Recently, cathepsin В 
was described to be important for activation of receptor-bound pro-uPA and invasion (177). 
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Migration-associated molecules 
Migration is also an important factor in metastasis. Several factors have been described to 
regulate random tumor cell motility, like autocrine motility factor (AMF) or scatter factor, which 
can be activated through a receptor activated G-protein (178-180). The receptor for AMF and 
scatter factor turned out to be gp78. Expression could be regulated by cytokines (181,182). 
Priming of B16F1 mouse melanoma cells by preventing internalization of the motility factor 
receptor enhanced pulmonary metastases. The receptor was localized in patches only in highly 
metastatic variants (183). RA decreased motility by decreasing the amounts of gp78 (184,185) 
without interfering with the subendothelial matrix. RA also affected levels of c-fos, and c-jun, 
which are induced by TPA in melanocytes, next to a reduction of tPA and collagenase IV 
(184,186). 
Since а ОЗ could be detected in focal contacts of cultured melanocytes it was postulated to be 
migration-associated (116). The integrin expression profile itself could also be altered by growth 
factors ((118), and refs. therein). Antibodies against the heparin-binding domain of FN inhibit 
haptotactic migration to this molecule (187). Collagen Г also stimulated motility by increasing 
the intracellular Ca2* concentration (188). 
Proteoglycans are also involved in this process. A change in the ratio of heparan sulphate and 
chondroitin sulphate proteoglycans (CSPGs) was described in relation to the onset of 
motility(189). Antibodies to a CSPG which were immunologically related to CD44, inhibited 
motility on collagen I and reduced invasive behavior (189). The same effect was observed after 
stimulation of motility by transforming growth factor В (TGFß) (190). A number of growth 
factors were described to modulate motility. IGF and granulocyte macrophage-colony stimulating 
factor (GM/CSF) stimulated migration of A20S8 melanoma cells in a dose-dependant way (191). 
Also hepatocyte growth factor (HGF)/scatter factor (SF) could promote motility but was not 
mitogenic without the presence of synergistic factors. Infection with retroviral HGF-constructs was 
not sufficient to confer the malignant phenotype (192). The nerve growth factor receptor (NGFR) 
was also not mitogenic but a mediator of migration (45). Mutations in c-kit, encoding a receptor 
tyrosine kinase resulted also in deficiencies in migration and proliferation of melanoblasts (193). 
Changes in components of the cytoskeleton, the most obvious candidates in this aspect, were 
also related with tumor progression. Keratins K8 and K18 were upregulated in a highly metastatic 
cell line. Coexpression of vimentin and keratin correlated to invasion and metastatic potential 
(194). In a study using patient lesions, consisting mainly of melanoma metastases, expression of 
keratin K8 was detected in 10 out of 15 melanomas, while all melanomas expressed vimentin 
(195). In a survey of 100 melanomas, keratin expression was found in 2-20% of the cases, 
depending of fixation methods (196). Remarkably, keratin expression was confined to the 
recurrent melanomas and melanoma metastases (196). The ability to organize stress fibers 
correlated with a higher random motility of melanoma cell lines (197). Vinculin, which is implied 
in focal attachments to the membrane, also showed a differential expression between high- and 
lowly metastatic B16 cells, the highest expression being present in the lowly metastatic cell line 
(198). 
Protein Kinase С (PKC) 
Since phorbol esters are often used in the media for melanocytes and PKC is directly activated 
by TPA (and downmodulated after prolonged exposure), many studies have focussed on the 
presence of PKC isoforms. Various isoforms of PKC were detected in melanocytic cells. 
Melanoma cell lines show expression of α and ePKC whereas the β-form is also present in 
melanocytes (199,200). Phorbol esters that stimulate PKC also enhanced B16 sublines 
experimental metastasis to the lungs (201), which could be diminished by PKC-inhibitors 
(201,202), although comparable numbers of cells were initially retained in the lungs (201). 
Transfection of the α-isoform into B16F1 cells led to a more differentiated phenotype (203) 
18 
whereas ßPKC transfectants failed to grow (2,204). In melanocytes isolated from newborns, PKC-
activity was parallelled by melanin content. flPKC was only present in pigmented cells pointing to 
a role of the B-isoform in melanogenesis (20S). PKC activity could also be increased by treatment 
with aMSH (206), a pigment-inducing melanotropin. No gross deletions or rearrangements could 
be detected in the flPKC gene (207). 
4. PROGRESSION MARKERS 
In order to find markers that distinguish between benign and malignant stages of melanocyte 
tumor progression, monoclonal antibodies haven been raised to melanoma or melanoma 
metastases. The application of monoclonal antibodies in cancer detection and therapy has been 
reviewed by Goldenberg (208). Many monoclonal antibodies have been described, that had a 
preferential expression for particular stages. Differentiation markers, present in the melanocyte 
cells and early stages can be lost during progression indicating that the tumor is poorly 
differentiated, like Kl .2 (209) or adenosine deaminase binding protein (ADAbp, identical to CD26 
or dipeptidyl peptidase IV) (69,210). 
ME491, which is antigenically identical to CD63, NKI/C3-antigen and the neuroglandular 
antigen (211), showed a preferential expression for the earlier stages of progression (212). 
Expression was strong on DN and early melanomas but declined in advanced and metastatic 
melanomas (213,214). The proportion of non-staining tumor cells was found to be increased in 
melanomas invading the dermis and in melanoma metastases (215). In Chapter 2, we describe a 
cDNA clone coding for this antigen by differential hybridization analysis comparing xenografts of 
early and advanced melanomas (216). Transfection of this clone into H-ras-transformed NIH/3T3 
cells partially suppressed the malignant phenotype in nude mice (217). CD9, another member of 
the ME491/CD63 family also showed preferential expression in primary melanomas rather than in 
metastases (218). CD9 expression correlated with HLA class I expression (218). 
The localization of all stages of melanocyte lesions in the skin has facilitated screening of large 
series of patient lesions. Many monoclonals were shown to be progression-associated. Some Mabs 
recognize known molecules, like ICAM-1 (P3.58) (106), VLA2 (Al.43) (219), the transferrin 
receptor (PAL-MI) (220,221), gangliosides (62,222), or melanotransferrin (p97)(223). Expression 
of PCNA (224) (proliferating cellular nuclear antigen, coding for an auxiliary protein for the 6 
DNA polymerase (225)) and КІ67 appeared to be proliferation associated and were also elevated 
during progression (224,226). Many markers have only been described in terms of molecular 
weight and glycosylation. Some progression markers are also present on cells of the immune or 
hematopoietic system. KP1 which recognizes CD68 on macrophages and myeloid precursors (227) 
showed reactivity on PM and MM, a small percentage of nevi, and none on melanocytes. Mab 
73.1, which binds the Fc receptor of NK cells and granulocytes (62) was also progression-
associated. 
HLA antigens are also hallmarks of neoplastic progression. HLA class II antigens were not 
detected in common nevi but were present on PM and MM (228,229). HLA class I proteins are 
prominently expressed on DN (230) in which the degree of expression correlates with an abnormal 
DNA content. Expression is reduced in tumors (231) and melanoma cell lines in which there is an 
inverse correlation with c-myc expression. Transfection of HLA class I into murine BL6 
melanoma cells led to the loss of melanoma-associated antigens (232). A melanoma clone derived 
from B16 lacking H-2b transfected with the H-2kb allele resulted in diminished experimental 
metastasis and homotypic adhesion not affecting its sensitivity to NK cells (233). 
Attention has been focussed on melanoma-associated antigens not present on normal tissue. 
These antigens could be very useful either as progression markers or in immunotargeting and the 
development of vaccins. Since the immune system may control the development of melanomas to 
a certain extent production of LAKs, TILs and CTLs may prove useful in evoking immune 
reactions (234). They should be reactive against melanoma-associated antigens which are not 
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expressed by normal cells (235). Recently, expression of such an antigen recognized by the 
immune system, termed MAGE-1 (melanoma antigen-1) was described in melanomas but not in 
normal tissue (23S) except for testis and was also present in other tumors of neuroectodermal 
origin (236). Patients immunized with vaccins prepared from what four cultured melanoma cell 
lines shed into the medium developed antibodies in 65% of the cases (237). While the 
development of possible vaccins is beyond the scope of this review (for a review , see ref. 
238,239), it would be of interest if this approach would lead to the identification of progression 
markers. 
5. DIFFERENTIAL AND SUBTRACTION SCREENING STRATEGIES 
A molecular strategy for the detection of either up- or down-modulated sequences comprises 
differential and subtraction hybridization techniques. Many differentially expressed clones have 
been isolated when looking for growth factor- or hormone-induced mRNAs, or as tissue specific 
transcripts. In tumor biology, it has been succesmlly performed in the isolation of differentially 
expressed clones in mammary (240-245), prostate (246-248), and colon carcinoma (249-252), in 
melanoma (216,253-255) and in Wilms' tumor (256). The technical aspects have been extensively 
reviewed by Schweinfest and Papas (257). One of the main advantages of this approach is that 
either novel sequences or known genes with an as yet unknown relation to tumorigenesis can be 
isolated. There is one prerequisite; the stages compared should not be too far apart in the case of 
animal models and human lesions should be derived from one patient only, unless large pools of 
patient lesions are used in order to concentrate on the genes of interest and eliminate trivial 
differences. Whereas differential hybridization assays often lead to the detection of differentially 
expressed clones with a high abundancy, subtraction hybridization techniques also enable us to 
isolate less frequently expressed messengers. Although the term subtractive suggests that only 
clones of interest are isolated, subtractive hybridization leads to enrichment. A factor thousand can 
be achieved in this way. Incomplete subtraction is due to incomplete hybridization and/or to an 
incomplete physical separation of hybridized and non-hybridized sequences. Less abundant 
messengers can also be isolated by using differential display (258) in which a subset of the 
mRNAs are partly amplified at the 3' end using arbitrary and oligo-dT primers including two 
other nucleotides at the 5'end. Amplified sequences are compared on a sequencing gel allowing 
comparison of more stages at the same time. At the DNA level subtraction hybridization has also 
been performed. Recently, a "representational difference analysis" (RDA) was described in which 
two DNA populations were represented by using different restriction enzyme fragments as 
ampi icons and ligated to different PCR adaptors (259). These ampi icons were used for subtraction 
and amplification. The conditions were chosen in such a way that only double stranded tester 
sequences containing the sequences of interest were amplified exponentially. In subsequent 
subtraction-amplification steps, target sequences will be present in higher concentrations thereby 
also making use of kinetic enrichment (260). An elegant approach combining the knowledge of 
chromosomal aberrations and cDNA subtraction hybridization was performed (245,256) using 
tumor material harboring a specific chromosomal aberration as the starting material for 
subtraction. 
Applications in melanoma research 
In the field of melanoma research the approach of differential and subtractive hybridization 
strategies have not been applied very often. Hutchins and coworkers isolated at least five novel 
genes when subtracting melanoma minus lung carcinoma sequences (261) in order to find 
melanoma-associated antigens. A number of X-ray inducible transcripts were isolated in 
radioresistant human melanoma cells (254), many of which could also be induced by UV 
irradiation or TP A. Three clones encoded already known genes; thymidine kinase, DT diaphorase 
(NAD(P)H:menadione oxidoreductase), and tPA. 
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nm23 was also isolated using these techniques and proposed to be a potential tumor-suppressor 
gene for melanoma (253,262). Eventually, nm23 turned out to be the human analog for 
Drosophila awd, which is implied in development of the larvae (263,264) and Dictyostelium 
nucleoside diphosphate (NDP) kinase (265), which has a role in the regeneration of GTPs and is 
associated with the formation of microtubuli. However, in several types of cancer including 
melanoma, there have been conflicting results. In neuroblastomas, elevated levels of nm23 were 
detected in advanced stage patients (266). In other solid tumors, elevated levels have also been 
reported (267). When looking at the expression of several variants of colon carcinoma, renal 
carcinoma, and melanoma cell lines and melanoma hybrids from metastatic and non-metastatic cell 
lines there appeared to be no correlation with their metastatic capacity (268). A low expression of 
nm23 in human melanomas correlated with a decreased survival time (269). Curiously, in a series 
of patient lesions, the overall expression in nevi was lower than in melanomas. 
By applying differential hybridization on xenograft material of two subsequent stages of 
melanoma progression, the radial growth phase including signs of early vertical growth, and the 
vertical growth phase we isolated calcyclin as a potential progression marker (216) as described in 
Chapter 2. In chapter 3, a large series of routinely fixed paraffin embedded patient lesions was 
screened. Expression of calcyclin was elevated in thick PM as compared to thin PMs 
corresponding with the transition into the vertical growth phase (270). Remarkably, expression 
was totally absent from dysplastic nevi. However, calcyclin could also be detected in the lower 
dermal part of common nevi. Calcyclin, originally isolated as a differentially expressed cDNA in 
serum-stimulated and quiescent cells (271,272), appears to be involved in signal transduction. 
Expression in pregnant mice stimulated lactogen II secretion (273). RNA in situ hybridization 
shows elevation of calcyclin expression in cells specialized in mucus secretion and a subset of 
hormone- and neurotransmitter-producing cells (274). Rabbit CAP50, a member of the annexin 
family (275,276) and bovine annexins II and VI were shown to bind calcyclin (277). In this 
respect, the localization of calcyclin to sites of exocytosis in the mouse (274) is interesting, since 
annexins are thought to be involved in membrane fusion and regulation of calcium-dependent 
events (278). Although Bazan et al. show an elevated expression of calcyclin concomitant with a 
greater part of cells entering the Gl phase, during corneal wound healing in rabbit eyes (279), 
Gong et al. show that this is the result of PKC activation. PKC inhibitors prevent TPA induced 
stimulation of calcyclin in endometrial carcinoma cells (280). Calcyclin expression was also 
stimulated by RA-induced differentiation of neuroblastoma cells (281). The mouse homolog of 
calcyclin, was described to be overexpressed in metastatic NIH/3T3 cells (282). Other members of 
the so-called S100 family of calcium-binding proteins, to which calcyclin belongs have been 
implied in melanoma. SlOOfl expression was detected at the onset of invasive behavior (283). 
S100B was shown to bind to p53 protein, thereby preventing its phosphorylation by PKC (284). 
We showed that 18A2/Mts-l/pEL98/BG12, already often shown to be involved in transformation 
and metastasis (271,285,286), was elevated in highly metastatic melanoma cell lines at the RNA 
level (unpublished results) which was reflected by amplification at the DNA level (216). Recently, 
another member of the S100 family was cloned after subtractive hybridization, that appeared to be 
downmodulated in breast carcinoma as compared to normal mammary epithelial cells (243). 
Another cDNA described in Chapter 4 that was differentially expressed in low- and highly 
metastatic melanoma cell lines appeared to be coding for thymosin BIO (ТОЮ), which has been 
shown to be a monomer-actin binding protein, thus providing a reservoir for G-actin (287-291) 
and possibly a regulator of polymerization (292). TfllO mRNA was elevated in melanoma 
metastases as compared to benign lesions. Microinjection of either thymosin A4 (TÛ4), the most 
abundantly expressed thymosin in mammalians, or TfllO resulted in a loss of stress fibers (293). 
Т6Ч was shown to have a 50-fold higher affinity for Mg.ATP.G-actin than the ADP-bound form 
(294). ADP-desequestration would be possible under physiological conditions (295). In contrast, 
profìlagrin, another monomeric-actin binding protein, which also binds to phosphatidyl inositol 
4,5 diphosphate (РГР2) (296) stabilizes actin filament forming by a higher affinity for the ADP-
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bound form, thus catalyzing the hydrolysis of ATP from G-actin. Interestingly, one point mutation 
in the actin-binding motif of TD4 changed this protein in an F-actin stimulatory one (297). 
Thymosins were also postulated as progression markers for renal carcinoma (298) and colorectal 
carcinoma (299). 
Using the same melanoma cell lines as were used for the isolation of TfllO, two more clones 
were isolated, designated NMA and NMB, which are downmodulated in metastatic melanoma cell 
lines and represent novel genes (Chapter 5). 
Up- and down-regulated genes in melanoma model systems and patient lesions during 
melanocyte tumor progression, identified by any of the five approaches mentioned above are 
schematically depicted in Figure 2. 
CONCLUSIONS AND FUTURE PROSPECTS 
Both tumorigenesis and the development of metastatic potential are highly complex processes. 
As described by Vogelstein and coworkers (300), it probably is most important that a certain 
number of changes occur, without the order being very important, although they are hallmarks in 
this progression. The application of progression markers might be useful within a panel of other 
markers, since many changes have shown to be gradual, and many so-called progression markers 
are also present in benign lesions, although to a lesser extent, which is to be expected if such a 
marker is important for key processes in the cell. Both the identification and functional 
characterization of the cDNAs that are coding for antigens which are recognized by monoclonal 
antibodies postulated as progression markers and of differentially expressed cDNAs or genomic 
sequences is essential to understand their role in tumorigenesis. Although model systems do not 
necessarily reflect the situation in vivo, they can be very helpful in determining the role of 
possible involved sequences. Even when no direct involvement in altering for instance the 
metastatic capability can be found, such a marker still can be useful as a clinical tool, whenever 
this marker discriminates between certain stages. The importance of these molecules may also lie 
in the modulation of the microenvironment facilitating other more important steps in the 
acquisition of invasive behavior of the tumor or by modulating the immune system of the host 
which is not addressed when using nude mice model systems. Even when this would also not be 
the case, revealing the underlying mechanism which leads to a differential expression should shed 
some light on the process itself. 
Molecular biological techniques have proven to be powerful tools for the identification of new 
genes whose expression is correlated with tumorigenesis and neoplastic progression. Next to the 
isolation of several oncogenes and potential suppressor genes involved, it might also be helpful in 
a further narrowing down of involved genes located on chromosomes which are aberrant in 
melanoma. Newly developed methods, like representational difference analysis, in which PCR 
has been applied to subtractive hybridization and used instead of physical separation techniques of 
unique target sequences, differential display, applying subtractive hybridization on hybrid cell 
lines containing a certain chromosomal aberration, and the application of PCR on material of 
frozen or paraffin sections, should accelerate the isolation of genes important in melanocytic 
tumor progression. 
OUTLINE OF Tins THESIS 
In this thesis, differential and subtraction hybridization methods have been used as an approach 
to isolate new potential progression markers for human cutaneous melanoma. In Chapter 1, 
differential hybridization has been applied to human lesions grafted to nude mice which 
represented two subsequent stages of melanocytic tumor progression. This resulted in the isolation 
of calcyclin as a potential progression marker. A further characterization of the expression of this 
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clone at the RNA and protein level in patient lesions is described in Chapter 3. In Chapter 4 and 5 
the method of subtraction hybridization was used to construct a cDNA library that was enriched 
for sequences with a preferential expression in high-metastatic human melanoma cell lines. 
Several clones were isolated with a differential expression in high- and low-metastatic 
melanoma cell lines. The isolation and expression of thymosin β 10 is discussed in Chapter 4. In 
the course of screening this library, two clones, designated NMa and NMb, were isolated whose 
expression appeared to be low or absent in high-metastatic human melanoma cell lines and high in 
low-metastatic ones. The characterization of NMb is described in Chapter 5. 
Figure 2: Melanocyte markers for tumor progression. 
Melanocytic markere that i n downrcgulatcd (left) or upregulated (righi) as reported for A; melanoma cell lines and model 
aystems, B; human advanced melanoma lesions. 
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ABSTRACT 
Sloe« our aim wu to isolale nul Identify new progression markers of 
human cutaneous melanoma, we applied the differential hybridization 
technique, in which we compared the gene expression la two subsequent 
stages of this progression. Tumors in nude nke arising after transplan­
tation and serial passage In riro of either the horizontally and early 
vertically growing part or the advanced vertically growing part of a 
primary melanoma of the same patient were used for this assay. This 
resulted In the Isolation of a number of complementary DNA clones that 
were differentially expressed. Based on the marked difference in expres­
sion, one of them, designated pMWl, was chosen for further character­
ization and appeared to be coding for calcyclin, a cell cycle-regulated 
protein, belonging to a family of small calcium-binding proteins. Calcyclin 
expression was elevated In hlgh-meUstatlc human melanoma cell lines 
In nude mice compared to low-metastatk ones Imuiunoprecipltation of 
calcyclin showed that the differential expression at the RNA level Is also 
reflected at the protein level. These findings show that expression of 
cakyclln Is related to metastasis of human melanoma cell Unes In nude 
mice and emphasize the role of this family of caldum-hlndlng proteins In 
neoplastic progression as was reported for the mease homologue of 
calcyclin and other members of the same family. 
INTRODUCTION 
Clinically and pathologically melanocytic tumor progression 
can be defined by several distinct stages (I). All lesions are 
thought to develop from melanocytes and represent subsequent 
stages of progression accompanied by increasing atypia. An 
early primary melanoma, characterized by horizontal growth 
(RGP),3 can develop into an advanced melanoma that is also 
capable of growth in the vertical direction (VGP) and ultimately 
of metastasis. 
The different steps in this progression can also be defined by 
immunohrstochemistry using monoclonal antibodies which rec­
ognize antigens with a preferential expression for one or a few 
stages of this process (2-4). In the last few years a number of 
such monoclonal antibodies have been developed. Some rec­
ognize adhesion molecules, such as intercellular adhesion mol­
ecule 1 (5) and very late antigen 2 (6), or growth factor receptor 
molecules such as the transferrin receptor (7) and the epidermal 
growth factor receptor4 (8), or glycoproteins with a function yet 
unknown. Although the development and characterization of 
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monoclonal antibodies provide a useful tool in identifying genes 
whose expression is related to either more benign or more 
malignant stages, it also has its restrictions. For example, it is 
difficult to produce antibodies directed against antigens which 
have a low antigenicity. Furthermore, it leads mainly to the 
detection of cell surface molecules. In order to isolate new 
progression markers we applied the differential hybridization 
technique comparing two subsequent stages of melanocytic 
tumor progression. In the last few years this technique has 
already proved to be successful in the isolation of cDNA clones 
that were either activated or deactivated (8-12) in melanoma 
and mammary and prostatic adenocarcinoma upon comparison 
of metastatic versus nonmetastatic cell lines or tumors. Among 
the genes that are down-regulated during progression toward 
metastasis there might be candidates for suppressor genes (13). 
The stages we compared by differential hybridization were 
the advanced vertical and radial growth phase, including early 
vertical growth, of a primary cutaneous melanoma of one 
patient. This particular melanoma contained both phases on 
top of each other, and since the material itself was insufficient 
for these assays, both parts were separately transplanted into 
nude mice, and the resulting tumors were used as starting 
material. 
To estimate the value of the cDNA clones we isolated this 
way we performed a Northern blot analysis using a panel of 
human melanoma cell lines that had already been shown to 
vary in their metastatic behavior in nude mice, in order to 
determine whether their expression was related to neoplastic 
progression and specifically to metastasis. Here we describe the 
characterization of one of them, designated pMWl, that ap­
peared to be coding for calcyclin, a small calcium-binding 
protein. 
MATERIALS AND METHODS 
Patient Material. The patient from whom the specimen was obtained 
was a 87-year-old male suffering from cutaneous melanoma at the 
temporal region The diagnosis was superficial spreading melanoma 
Clark level IV and a Breslow thickness of S 25 mm In the tumor a flat 
intraepidennal and subepidermal component (interpreted as radial 
growth phase with early vertical growth) and an adjacent intradermal 
nodule (interpreted as advanced vertical growth phase) were discerned, 
both macro-and microscopically (Fig 1) 
Xenografts. Pieces of 1-2 mm1 of different components (RGP and 
VGP) of one human melanoma lesion were transplanted s с. into nude 
mice (nu/rui BALB/ç Laboratory Breeding and Research Center, Bom-
holtgaard, Ry, Denmark) and serially passaged in mo by s с transplan­
tation of the resulting tumor Xenograft tissue of the first few passages 
was used to isolate RNA for the construction of probes and libraries 
In the case of cell lines, approximately 1-2 x 10* cells were inoculated 
s с. and passaged as described 
CeU Lines Human melanoma cell lines IF6, 510, M14, Mel57, BLM 
(14, 15), MV3 (16), and MVI (17) were grown as monolayers on 
Dulbecco's modified Eagle's medium supplemented with 10% fetal calf 
serum, glutamin (2 тч), penicillin G (100 units/ml), streptomycin (100 
Mg/ml), and pyruvate (I тм) Aliquots were trvpsinized and frozen at 
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Fig. 1. Histopathological examination of the primary cutaneous melanoma 
reveals an intraepidermal and subepidermal component, interpreted as radial 
growth phase with early vertical growth phase (R), and an adjacent intradermal 
nodule, representing advanced vertical growth phase (V). H & Ε, χ 4. 
—70'C for either RNA or DNA isolations. MV1 was developed from 
the same melanoma as MV3 and represents the lower metastatic variant 
of the two cell lines. MV1 cells from the 7th passage did not give any 
metastases in nude mice at all, and MVI cells from the 11th passage 
gave rise to metastases in about 10% of the cases. For our assays we 
used cells from the 9th passage. 
In our panel of cell lines, IF6, 530, M14, and MVI represent the 
non- or low-metastasizing cell lines. MeI57 produces spontaneous 
metastases in about 15% of the cases. The highly metastatic cell lines 
in our panel are the BLM (50-60%) and MV3 (90-95%) (16). 
RNA Isolation and Northern Blot Analysis. Total RNA was isolated 
using the lithium-urea procedure as described by Auffray and Rougeon 
(18). Oligodeoxythymidine selections were performed using oligodeox-
ythymidine columns (type II; Collaborative Research, Bedford, MA). 
Ten μg of total RNA were glyoxylated (19), size fractionated on 1% 
agarose gels, and blotted on Hybond N or Hybond N-plus (Amersham, 
England) according to the procedure recommended by the manufac­
turer. To reconfirm that equal amounts were loaded in each lane the 
blots were hybridized afterward to a 28S ribosomal probe. 
Construction of cDNA Libraries. cDNA libraries were constructed 
from 5 μg of oligodeoxythymidine-selected RNA using a cDNA cloning 
kit (Pharmacia, Uppsala, Sweden). The cDNA library representing the 
VGP was constructed in Xgtl 1 (Promega, Madison, WI). 
Construction of DNA and RNA Probes: Hybridization. RNA probes 
were constructed using reverse transcriptase from the Moloney murine 
leukemia virus (BRL, Grand Island, New York) according to the 
procedure recommended by the manufacturer. The first strand synthesis 
was followed by hydrolysis of the RNA by adding, in a final concentra­
tion, 10 т м EDTA, 0.3% SDS, and 0.15 м NaOH and incubating for 
30 min at 60°C, after which the solution was neutralized by adding 
0.15 M acetic acid and 0.07 м Tris-HCl, pH 7.5. The total reaction 
volume was 30 ді. The single-stranded cDNA was precipitated using 
5-10 Mg of mussel glycogen as a carrier, dissolved in 5-10 μΐ of water, 
and radiolabeled using the mult ¡prime labeling method as described by 
Amersham. DNA probes were also labeled this way. 
The hybridizations of the cDNA libraries were performed as de-
scribed (20). The hybridizations of Northern blots were performed 
according to the method of Church and Gilbert (21) with the addition 
of 0.1 mg denatured herring sperm DNA/ml of hybridization mixture. 
Southern blots were hybridized according to the procedure as recom-
mended by Amersham. 
DNA Isolation and Southern Blot Analysis. Chromosomal DNA was 
isolated based on the method of Blin and Stafford (22) with minor 
modifications. Samples of DNA were digested using restriction en-
zymes £coRI, BamHl, or Η indili, and 10 μ% were size fractionated on 
1 % agarose gels. The DNA was transferred to Hybond N-plus (Amer­
sham) according to the protocol described by the manufacturer. As a 
control on the amount of DNA loaded in each lane the blot was 
hybridized to a chromosome 18-specific centromeric probe. 
Differential Hybridization Assay. After plating of the library two 
replica filters were made of each plate. One replica was screened with 
a probe representing the advanced VGP mRNA population; the other 
one was hybridized to a probe representing the mRNA isolated from 
the tumors derived from the RGP, including early vertical growth. The 
resulting sets of autoradiographs were compared, and the cDNA clones 
corresponding to a marked difference in expression between these stages 
were selected for further screening. After three rounds of additional 
screening differentially expressed clones were isolated, and the inserts 
were radiolabeled and hybridized to Northern blots containing two 
human melanoma cell lines (MV1 and MV3) with different metastatic 
capacities in nude mice. Finally, as a control on their relation with 
metastasis they were also hybridized to a panel of seven human mela­
noma cell lines (including MV1 and MV3) with known metastatic 
potential in nude mice. 
DNA Sequencing and Computer Analysis. DNA fragments were li-
gated into Ml3mpl8 or mpl9 and sequenced according to the dideoxy 
method as described by Sanger et ai (23). Sequences were determined 
from both strands of the cloned cDNAs. Searches for known sequences 
were performed using the Genbank and EMBO databases (24, 25). 
Cell Labeling and Immunoprecipitation. Cell labeling and isolation of 
proteins were based on the method described by Banks-Schlegel and 
Harris (26). For cell labeling MV3 or MV1 cells were grown in 3.5-cm 
(o) dishes in 1.5 ml of methionine free Eagle's minimum essential 
medium for 1 h, followed by the addition of 90 μΟ of [,5S]methionine 
(>1000 Ci/mmol; Amersham) and a final concentration of 6% of 
dialyzed fetal calf serum. After overnight incubation at 37*C the cells 
were rinsed three times with phosphate-buffered saline. Seventy μΐ of 
lysis buffer (20 т м Tris, 1 т м phenylmethanesulfonyl fluoride, 2% 
SDS, 10 т м dithioerythritol) was added, resulting in lysis of the labeled 
cells. The lysates were boiled for 10 min and centrifuged to pellet 
insoluble material. The supernatant was diluted in 1.5 ml of RIPA 
buffer without SDS (26) followed by centrifugation for 10 min. The 
resulting supernatant was used for immunoprecipitation. Polyclonal 
antibodies were raised in rabbits and affinity purified (27). Aliquots 
containing 5 x 106 cpm of [3SS]methionine-labeled cell extracts or 1.7 
μg of proteins were used for each precipitation. The protein concentra­
tion of the lysates was determined using the BioRad protein assay 
(BioRad, Richmond, CA). Immunoprecipitates were washed three times 
with RIPA buffer, once with RIPA buffer containing 25 т м KCl, and 
once again using RIPA buffer. Finally, the precipitates were analyzed 
on a 15% SDS-polyacrylamide gel, after which the gel was dried, 
fluorographed, and exposed to Kodak X-Omat AR-5 films. 
RESULTS 
Isolation and Identification of Differentially Expressed Clones. 
We constructed a cDNA library of approximately 800,000 
recombinant clones corresponding to the advanced VGP of a 
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Fig. 2. Northern blot analysis of melanoma cell lines M VI {left lane) and M V3 
(right lane). Each lane contains 10 i*g of total RNA. The molecular probes used 
were pMW4 (A), pMW5 (B), and pMWl (C). The molecular weight marker was 
XDNA digested with restriction enzyme HindlW.A (bottom), control hybridization 
using a 28S ribosomal probe. 
Expression of Calcyclin in Rat Organs. For further character­
ization calcyclin expression was examined in normal rat organs 
using Northern blot analysis and pMWl as a probe. Expression 
of calcyclin was restricted to a few organs (Fig. 4). The highest 
expression was found in urinary bladder and prostate, followed 
by the lung, stomach, and finally the intestines. No signal was 
observed in liver, brain, striated muscle, testis, and thymus. 
Only after a longer exposure very weak bands could be seen in 
spleen, kidney, and heart (data not shown). 
Southern Blot Analysis. In order to determine whether gene 
amplifications or rearrangements could be responsible for the 
elevated expression in the highly metastatic melanoma cell 
lines, a Southern blot was screened with pMWl as a probe. 
Although no major gene rearrangements could be detected (Fig. 
5), the intensity of the bands in Lanes £ and F containing DNA 
of the BLM and MV3 cells was higher than in the non- or less 
metastasizing cell lines, indicating that a slight amplification of 
the calcyclin gene parallels the elevated expression at the RNA 
level. When scanned densitometrically and correcting for load-
ing differences using the three bands that were detected after 
hybridization with a chromosome 18-specific probe (see Fig. 
5), the amplification was estimated to be 2-fold upon compari-
son to the 1F6, M14, and Mel57 cell lines and a factor of 4-5 
when compared to the 530 and MV1 cell lines. Another chro-
mosome 1-specific probe, BG12, coding for the human homo-
logue of the murine placental calcium-binding protein and 
mapping to a region close to the region to which the calcyclin 
gene was mapped (lq21-25; Ref. 30), showed a similar pattern, 
primary human melanoma. After 3 rounds of differential 
screening using radiolabeled probes derived from the RNA of 
the VGP or the RGP, including early VGP, six clones were 
isolated whose expression was studied initially in two human 
melanoma cell lines, the highly metastatic MV3 cell line and 
its less metastatic variant, the MV1 cell line. The expression of 
three of these clones, designated pMWl, pMW4, and pMW5, 
seemed to be related to metastatic potential (Fig. 2). To support 
this impression these clones were labeled and hybridized to a 
Northern blot containing seven melanoma cell lines that had 
already been shown to vary in their metastatic behavior in nude 
mice (15). 
pMW4 showed a high expression in the less metastatic cell 
lines (data not shown). Sequence analysis demonstrated this 
clone to be identical to ME491, a melanoma antigen associated 
with the early stages of melanoma tumor progression (28). 
pM W5 recognized two messenger RN As of about 0.7 and 1.0 
kilobases (see also Fig. 2), one of which appeared to be differ-
entially expressed. The expression was highest in the Mel57, 
MV3, and BLM cell lines (data not shown). Based on the large 
difference in expression pMWl was chosen for further study. 
The expression of pMWl was highest in the two highly 
metastatic BLM and MV3 cell lines corresponding to an 
mRNA of about 600 base pairs (shown in Fig. 3). The expres-
sion in IF6 cells in contrast to the other non- or less metasta-
sizing cells appeared to be relatively high. However, this cell 
line does not give rise to any metastases. Sequence analysis 
showed pMWl to be 100% homologous to the cDNA coding 
for calcyclin (434 base pairs), a calcium-binding protein. pMWl 
was 362 base pairs in length and stretched from position 33 to 
395, covering the complete coding region (base pairs 66-336). 
In this region, no mutations were found upon comparison to 
the published calcyclin sequence. It was also described as a 
prolactin receptor-associated protein (29). 
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Fig. 3. Northern blot analysis of several human melanoma cell lines. Ten g^ 
of total RNA were loaded in each lane. Lane A; IF6; Lane B, 530; Lane C, M14; 
Lane D, Mel57; Lane E, BLM; Lane F, MV3; Lane G, MV1. The blot was 
hybridized to radiolabeled pMWl. The molecular weight marker was XDNA 
digested with restriction enzyme Hindi)]. Bottom, control hybridization, using a 
28S ribosomal probe. 
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Fig. 4. Northern blot analysis of several rat organs. Ten ng of total RNA were 
loaded in each lane. Lane 1, spleen; Lane 2, liver; Lane 3, brain; Lane 4, heart; 
Lane 5, striated muscle; Lane 6, kidney; Lane 7, testis; Lane 8, thymus; Lane 9, 
prostate; Lane 10, lung; Lane 11, bladder; Lane 12, intestines; Lane 13, stomach. 
pMWl was used as a molecular probe. The molecular weight marker was XDNA 
digested with restriction enzyme Hindlll; a 28S ribosomal probe was used for the 
control hybridization. 
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Fig. 5. Southern blot analysis of several human melanoma cell lines. Each lane 
contains 22 iig of chromosomal DNA digested with restriction enzyme ¿7a>RI 
The molecular weight marker was ADNA digested with Hindlll. Lane A, 1F6; 
Lane B, 530; Lane C, M14; Lane D, Mel57; Lane E, BLM; Lane F, MV3; Lane 
G, MV1. The blot was hybridized with pMWl as a molecular probe. As a control 
on the amount of DNA loaded, the same blot was hybridized afterward to a 
chromosome 18 specific probe (three bands of around 20,1.3, and 0.6 kilobases). 
Abnormalities involving chromosome 18 have not been described in relation with 
melanoma. The same blot was hybridized to a chromosome I-specific probe, 
BG12, mapping to a region ( lul 2-22) close to the region to which calcyclin was 
mapped (lq21-25), to determine whether a larger part of chromosome 1, except 
for the calcyclin gene, was amplified. 
volumes containing equal amounts of incorporated counts (Fig. 
6, Lanes A and I!) as well as equal amounts of protein (Lanes 
C-F) were used to perform the immunoprecipitation. The 
signals obtained clearly indicate that the expression of calcyclin 
(approximately 10.5 kDa; arrow) is higher in the MV3 cells 
(Lanes В and D) than in the MV1 cells (Lanes A and C). 
Calcyclin was specifically precipitated, since the band is absent 
in the controls, when we used rabbit preimmune serum instead 
of the polyclonal antibody (Lanes E and F) or protein A-
Sepharose without the addition of either preimmune serum or 
polyclonal antibody (Lane I). 
DISCUSSION 
Since our aim in this study was to isolate cDNA clones whose 
expression was associated with one or a few subsequent stages 
of melanocytic tumor progression, we constructed a cDNA 
library derived from the advanced vertically growing component 
of a primary cutaneous melanoma. Differential screening using 
probes corresponding to the advanced VGP or the RGP, in­
cluding early VGP, of the same melanoma finally resulted in 
the isolation of three differentially expressed clones. Because 
metastasis is by far the most clinically relevant step in neoplastic 
progression, we focused on a panel of human melanoma cell 
lines with varying metastatic potential in nude mice as our final 
control on differentially expressed clones. Sequence analysis 
demonstrated pMW4 to be coding for ME491, a melanoma 
antigen associated with the early stages of tumor progression. 
pMW5 and pMWl both showed an elevated expression in the 
16 
indicating that this part of the chromosome might be more 
aberrant in the BLM and MV3 cell lines. 
Immunoprecipitation of Calcyclin. The incorporation of ["S] 
methionine in the MV3 cells was twice as high as the incorpo­
ration in MV1 cells. This was not surprising, since the MV3 
cells also grow approximately 2.5-fold faster in vitro. However, 
the amount of protein present in the labeled MV3 cells was 
higher than in the M VI cells by only a factor of 1.2-1.4. In 
order to compare the amounts of immunoprecipitated calcyclin, 
Fig. 6. Immunoprecipitation of calcyclin. The following were used for the 
precipitation Lane I. 5 χ 10* cpm of labeled MV] cells; Lane B, 5 x 10* cpm of 
labeled MV3 cells; Lane C, 1.7 «g of MV1 proteins; Lane D, 1.7 ,ig of MV3 
proteins; Lane E, rabbit preimmune serum and 1.7 μg protein of MV 1 cells; Lane 
F, rabbit preimmune serum and 1.7 ng of protein of M V3 cells; Lane I, protein 
A-Sepharose and 5 χ 10* cpm of labeled M V3 cells. Half of the immunoprecipitate 
(corresponding to 1000-1400 cpm) was loaded onto a 15% SDS-polyacrylamide 
gel. Lanes G and //. aliquots (approximately 1500 cpm) of the labeled M VI cell 
lysate {Lane G) or the M V3 lysate ( lam' H). In Lanes Α-D, immunoprecipitated 
calcyclin can clearly be seen {arrow). 
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metastatic human melanoma cell lines. Based on the marked 
difference in expression pMWl was chosen for further study 
and appeared to be coding for calcyclin. Calcyclin or 2Λ9 is 
cell cycle regulated, and its expression can be induced by serum, 
platelet-derived growth factor, or epidermal growth factor (31). 
It was identified by differential hybridization comparing quies­
cent and serum-stimulated fibroblasts and was originally iso­
lated from Ci-specific temperature-sensitive mutants from baby 
Syrian hamster kidney cells (32). It has been found to be 
overexpressed in human myeloid leukemias (31) and is present 
in some but not all human breast cancer cell lines (29). Mtsl/ 
pEL98/18A2, a member of the S100 family to which calcyclin 
belongs and, like calcyclin, a cell cycle-regulated protein (31), 
was found to be elevated in several metastatic cell lines (33) 
and in murine fibroblasts transformed by either activated on­
cogenes or chemical carcinogens (34). Very recently, when 
monoclonal antibodies against either the a or the β subunit of 
S100 on human melanocyte lesions were used, monoclonal 
anti-S100/3 reactivities were found to be absent in the earlier 
stages of melanocyte tumor progression but could be detected 
once vertical growth or invasiveness began (35). Also, recently, 
the mouse homologue of calcyclin was found to be elevated in 
nu-transformed metastatic NIH/3T3 cells (36). We found that 
calcyclin expression was highest in the highly metastatic BLM 
and MV3 cell lines compared to the less metastatic ones; 
however, IF6 also showed a relatively high expression, although 
this cell line does not give rise to any spontaneous metastases 
in nude mice. IF6 is the only nonmetastatic cell line tested 
showing a slightly higher expression. The immunoprecipitation 
of calcyclin in the MV1 and MV3 cells indicates that the 
differences at the RNA level are also reflected at the protein 
level. Our study further emphasizes the relevance of the mem­
bers of this family and shows for the first time that in our 
melanoma model system there is a relation of calcyclin expres­
sion with metastatic behavior in nude mice. 
The elevated expression of calcyclin in the highly metastatic 
melanoma cell lines could partly originate in a slight amplifi­
cation of the corresponding gene, although it could not account 
directly for the large differences at the RNA level. The elevated 
level of the mRNA might be caused by transactivating factors 
or some kind of cascade leading indirectly to an elevated mRNA 
level. Interestingly, the calcyclin gene has been mapped to 
chromosome 1 (37) like the genes coding for other calcium-
binding proteins (38). Additional copies of lq have repeatedly 
been reported in melanoma and other lesions (39, 40). Prelim­
inary in situ hybridization experiments on interphase nuclei 
with a chromosome 1-specific probe hybridizing to the lql2 
region indicate that in the BLM and MV3 cell lines there is a 
population of cells containing a high copy number of (part of) 
chromosome 1' that is absent in the other cell lines. However, 
this population accounts for only 10-20% of the cells. Another 
probe, BG12, which maps to a region close to the region to 
which calcyclin is mapped and which codes for the human 
homologue of the murine placental calcium-binding protein 
(another member of the S100 family), showed a pattern similar 
to that of calcyclin at the DNA level in the BLM and MV3 cell 
lines, indicating that more aberrations involving that part of 
the chromosome are present in the BLM and MV3 cell lines 
than in the other cell lines studied. Numerical and structural 
' P. E. J. de Wit, A. H. N. Норлшл, С. N. P. van Muljen. D. F. С. M. Smetti, 
J. L. M Beck, О. Moesker, and D. J. Ruller, ¡η ¡ini detection of supernumerary 
aberrations of chromosome-specific repetitive DNA targets in interphase nuclei 
in human melanoma cell lines and tissue sections, J Invest. Dermatol., In presa, 
1992. 
aberrations involving chromosome 1 have been found in other 
carcinomas (40,41), and this could be related more to neoplastic 
progression in general (42). 
For further characterization we examined the tissue distri-
bution of calcyclin at the UNA level. The organs showing a 
high expression of calcyclin (bladder, prostate, lungs, stomach, 
and to a lesser extent the intestines) also contain a moderate to 
high amount of smooth muscle cells. Since calcyclin could also 
be purified from mouse stomach smooth muscle (27), the high 
expression, especially in prostate and urinary bladder, might be 
due to the expression in smooth muscle cells. This could be 
checked by applying mRNA in situ hybridization to sections of 
tissue expressing calcyclin. As far as they overlap, our data are 
largely in agreement with the data published for rat tissue 
distribution in which the highest expression was found in the 
lung, kidney, and uterus (29). The expression in prostate and 
bladder was not examined in this study. The high expression in 
uterus might also be due to a high expression of calcyclin in 
smooth muscle cells. However, we do not find a high expression 
in the kidney. In contrast, in a study using mouse organs, 
prostate was classified in the same range as brain, spleen, and 
testis, which showed low levels of expression (36). This could 
possibly be due to differences between species or preparation 
methods. 
The S100 family to which calcyclin belongs is part of a larger 
superfamily of calcium-binding proteins (the binding structure 
has been named the EF hand and is also known as calcium-
binding fingers). All members of the S100 family contain two 
EF hands. Other calcium-binding proteins of this superfamily 
include calmodulin, parvalbumin, and oncomodulin. Oncomo-
dulin has been shown to be present in transformed cells of 
diverse origins (43). Although some calcium-binding proteins 
have been implicated in neoplastic progression or metastasis, 
little is known about the function of the members of the S100 
family, pl i , a subunit of calpactin, a major substrate for tyro-
sine kinase, has been suggested to be important in membrane-
cytoskeleton interactions. MRP8 is probably identical to the 
cystic fibrosis antigen. Both MRP8 and MRP 14 are thought to 
be involved in inflammatory reactions. S100 proteins can affect 
microtubuli (dis)assembly and protein phosphorylation, and 
S1000 dimers can promote neunte outgrowth. Although these 
proteins are all structurally alike, the effects they produce seem 
unrelated. A possible underlying mechanism has been suggested 
to be the alteration of the degree of phosphorylation by which 
they would exert their actions (44). 
Since calcyclin expression is involved in cell cycle progres-
sion, can be induced by certain growth factors, and binds to 
calcium, it is likely to be linked to signal transduction pathways. 
To be able to further characterize the biological effects of 
calcyclin expression in tumor progression and metastasis, we 
intend to do transfection experiments using less metastatic 
melanoma cells, which might provide some answers in that 
direction. 
The role of calcyclin in neoplastic progression still remains 
to be elucidated. However, its function is particularly intriguing, 
since the elevated expression of other calcium-binding proteins 
has already been associated with malignant transformation or 
metastasis. 
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ABSTRACT MATERIALS AND METHODS 
When compering two subsequent stages of raelenocylk tumor progres­
sion we identified calcyclin os a new potential progression marker, the 
expression of which was correlated with metastatic behavior of various 
human melanoma cell lines In nude mice. ID this study, we describe a good 
correlation between RNA and protein levels ID (he xenografts of these cell 
lines and extended these experiments to a panel of 120 routinely processed 
human meUnocylic cutaneous lesions* Northern blot analysis demon­
strated that calcyclin RNA expression was elevated In melanoma metas­
tases as compared to several types of nevocellular nevi. Calcyclin staining 
using a specific polyclonal antiserum showed a more complex pattern. A 
stronger staining In a higher percentage of positive cells was observed In 
thick primary melanoma (&1.5 mm) as compared to thin primary mela­
noma (<1J> mm) Calcyclin expression was also present In a higher per­
centage of cells showing a stronger staining in melanomas with higher 
Clark levels (>II) corresponding to the vertical growth phase of primary 
melanomas. Protein expression In nevocellular nevi was confined to the 
dermal part and was highest In the lower parts of the dermis. Remarkably, 
dysplastic nevi (atypical moles), potential precursors of melanoma, did not 
show any expression at all, either in junctional or dermal parts. Confine­
ment of the expression to the dermal part of nondysplastic nevi and 
primary melanomas may reflect interactions with the mlcroenv iron ment 
of the reticular dermis that occurs with vertical growth. 
INTRODUCTION 
Calcyclin was originally isolated from G,-specific temperature-
sensitive mutants from baby Syrian hamster kidney cells (1) and was 
identified by differential hybridization comparing quiescent and se­
ni m-stimulaled fibroblasts as a cell cycle regulated gene (2) Its ex­
pression was found to be highest at the G
 t -phase of (he cell cycle and 
it could be induced by several growth factors including platelet-
derived growth factor and epidermal growth factor 
Calcyclin belongs to the so-called SlOO-family of small proteins 
containing two EF hands that form the calcuim-binding structures It 
has been shown lo bind both ?inc and calcium (3), was delected in 
some human breast cancer cell lines (4), and was found to be over-
expressed in human myeloid leukemias (2) The mouse homologue of 
calcyclin, 5B10, was found to be elevated in ras-transformed meta 
static NIH/3T3 cells (5) 
When applying the differential hybridization technique comparing 
two subsequent stages of melanocytic tumor progression to identify 
new progression markers for human cutaneous melanoma we isolated 
several clones, one of which appeared to be coding for calcyclin (6) 
The stages compared were the radial growth phase including early 
vertical growth of a primary melanoma and the more advanced ver­
tical growth phase of the same melanoma Calcyclin expression was 
elevated in highly metastatic human melanoma cell lines as compared 
to the lower metastatic ones Since two other members of the S100 
family, S100ß and pEL98/18A2/mtsl, were also described to be as-
sociated with neoplastic progression or metastatic behavior (7 -9 ) the 
correlation of calcyclin expression with metastatic behavior is intrigu-
ing and, therefore, we sought to determine the expression pattern of 
calcyclin in human melanocytic tumor progression 
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Cell Unes and Xenografts. Human melanoma cell lines 1F6. 530, M14, 
Mel57, BLM (10, 11), MV3 (12), and MV1 (13) were cultured as described 
before (6) Approximately 2 x ID6 cells were inoculated s c into nude mice 
{nu/nu BALB/c, Laboratory Breeding and Research Center, Bomholtgaard. Ry, 
Denmark) to produce xenograft tumors Within this panel of cell lines BLM 
and MV3 are the highly metastatic cell lines (ι e, spontaneous metastases 
occur in more than 50% of the lumor-bcaring animals) Mel57 produced 
metastases in about 15% of the tumor bearing animals The metastasis rate of 
1F6, 510, M14, and MV1 was less than 10% 
Human Material. After excision, representative parts of melanoma me 
tasiases or slices of NN,3 DN or atypical moles, or CN, of which most of the 
surrounding skin tissue had been cut off were snap-frozen in liquid nitrogen, 
and stored at -70°C Remaining tissue was used for conventional histopathol-
ogy The material that was used for RNA extractions for Northern blot analysis 
consisted of pools of tissue from multiple specimen of various types of nevi 
and skin Normal skin was obtained from patients who had also developed 
melanoma, and nevi were obtained from patients without any history of mela 
noma, except for one person Nine NN were pooled from 7 persons and 
consisted of 5 nevi of the compound type and 4 of the dermal type Nineteen 
DN from 15 persons showed slight (14 cases) or moderate atypia (5 cases) CN 
were all of the intradermal t>pe and varied in size from relatively small 
(diameter < 1 cm, 5 lesions) to rather Urge (8 χ 3 χ 0 4 cm 1 lesion) Twelve 
melanoma metastases were processed individually 
For calcychn-staining paraffin sections of NN, DN. MM, PM. CN or SN of 
routinely processed material were used Classifications were made based on 
histopathologic«! examination Of 25 NN obtained from 23 persons 5 were 
junctional nevi and 6 were of the dermal type The remaining 14 consisted of 
compound nevi Seven of 22 DN, obtained from 21 patients, showed severe 
atypia, 10 of which were moderale and 5 of which were slight Thin primary 
melanomas (Le, Breslow thickness was <1 5 mm) were diagnosed as super­
ficial spreading melanoma of varying Breslow thickness ( 0 3 1 1 mm) and 
Clark levels (I-IV) Three cases were diagnosed as lentigo malignant mela 
noma Thick PM (Breslow thickness of 2 1 5 mm) had a Breslow thickness of 
15-7 0 mm and Clark levels III-V, diagnoses were nodular melanoma (13 
cases), superficial spreading melanoma (4 cases), or acrolentiginous melanoma 
(2 cases) Metastases from various sites were used (both locoregional and 
distant metastases) Thirteen CN varied in size from small ( 1 x 1 x 0 4 cm) to 
relatively large (10 χ 3 χ 0 8 cm) Sixteen SN were stained 
RNA Isolation and Northern Blot Analysis. Total RNA was isolated as 
described by Auffray and Rougcon (14) Ten μg of RNA were blotted on 
Hybond N-plus (Amersham, bngland) according to the procedure recom­
mended by the manufacturer, after glyoxylation (15) and size fractionation on 
1% agarose gels To reconfirm equal loading the blots were hybndized after 
wards to nbosomal RNA probes 
Probes and Hybridization. Probes were radiolabeled using the multipnme 
labeling method as described by Amersham Hybridizations were performed 
according to the method of Church and Gilbert (16) with the addition of 0 1 mg 
of herring sperm DNA/ml of hybridization mixture 
Preparation оГ Polyclonal Antibody. A synthetic peptide TTGSKXQDAE-
LARL, situated in the region between the two EF hands corresponding to 
position 42-55 of the calcyclin protein in a heterologous region of the members 
of the S100-family (see Fig 1) was covalcntly linked to bovine serum albumin 
(17) and used to immunize rabbits For immunization 3 mg were inoculated 
intracutaneous!) together with Freund *s Complete Adjuvant Rabbits were 
buostered after 4, β, and 12 weeks by s c inoculation of 1 5 mg of calcyclin-
peplide and Freund's Incomplete Adjuvant 
J
 The abbreviations used are NN nevocellular nevus DN dysplastic nevus (atypical 
mole) CN congenital nevus SN, SpiLz nevus MM, melanoma metastasis, ΡΚ.Γ protein 
kinase C, PM primary melanoma 
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Fig. 1. Comparison of the predicted amino acid sequences of various members of the S100 family in the region between the two EF hands (parts of the EF hands are shown doublt 
underlined): hCALC. m5B10. and rPRA: human (2). mouse (5). and rat calcyclin (4); bSlOOa, bSIOOß: bovine a and β chains of S100 (32, 33); hSlOOß: human β chain of S10C 
(34); hMRP8 (also identified as the cystic fibrosis antigen; Ref. 35) and hMRP14: human migration inhibitory f actor-related proteins (36); bPll: bovine pll (37); ml8A2: mouse 18A2 
(38). The synthetic peptide is underlined. 
Calcyclin Staining of Paraffin Sections. Four-μιη sections were cut from 
paraffin blocks and mounted on glycin or poly-i.-lysin coated slides. Staining 
was performed using the ABC kit (Vector, Burlingame, CA). The sections were 
incubated with the primary polyclonal antibody in phosphate-buffered saline/ 
bovine serum albumin (1%) overnight at 4°C using a 1:750 dilution of the 
ammonium sulfate precipitated fraction (35 μg/ml). Blocking experiments 
were performed likewise with the addition of cither unrelated peptides con­
taining the RGD or LDV sequences or synthetic SlOOa or SlOOß peptides 
situated in the same region as the calcyclin peptide (100 μg/ml), calcyclin-
peptide at two concentrations (2 and 100 μ&/ιη1) or purified calcyclin, gener­
ously provided to us by Dr. J. Kuznicki (80 μg/ml). to the incubation mixture. 
Scoring was performed semiquantitative^ as negative, weak, moderate, or 
strong. The estimated amount of positively staining cells/lesion was divided 
into six classes: 1-5; 5-10; 10-25; 25-50; 50-75; and 75-100%. 
RESULTS 
Expression of Calcyclin m RNA and Protein in Xenografts. In a 
previous study we found a correlation between calcyclin expression in 
human melanoma cell lines and their metastatic potential. To deter­
mine whether this correlation could be extended to the xenografts of 
these cell lines we screened a Northern blot containing RNA isolated 
from xenografts of low-metastasizing cell lines (1F6, 530, M14, and 
Mel57) and two high-metastasizing cell lines (BLM and MV3) for 
expression of calcyclin RNA (Fig. 2). As expected, expression was 
highest in the BLM and MV3 xenografts (elevation of expression was 
determined to be at least 10-15-fold). 530 and Mel57 also showed an 
elevated expression (2- and 6-fold when compared to 1F6, M14, and 
MV1). In paraffin-embedded tissue sections stained with a polyclonal 
anti-calcyclin serum, a good correlation between RNA and protein 
levels was found in all xenografts (results not shown). 
Expression of Calcyclin mRNA in Patient Lesions. Hybridiza­
tion of a Northern blot containing RNA from various human melano­
cyte lesions with calcyclin showed a clear elevation of expression in 
10 of 12 melanoma metastases as compared to the different types of 
M e l 5 7 BLM 
Fig. 2. Northern blot analysis of 10 μg of total RNA isolated from human melanoma 
xenografts, using calcyclin as a molecular probe. As a molecular weight marker. A tfi/tdlll 
was used (only the lower bands are shown). Bottom, a control hybridization (28S rRNA). 
kb, kilobases. 
nevi (Fig. 3). Elevation was estimated to be 2.5-9-fold as estimated by 
densitometrical scanning when normalizing for 18 and 28S rRNA 
values. CN showed a slight elevation (1, 5-2X)as well as normal skin 
tissue (2-fold) when compared to NN. 
Calcyclin Staining of Human Melanocytic Lesions. In order tc 
evaluate the significance of calcyclin as a progression marker, a large 
series of human melanocytic lesions was stained with a polyclonal 
anti-calcyclin antibody. The synthetic peptide which was used tc 
immunize rabbits was chosen in such way that cross-reaction with 
other members of the SlOO-family is highly improbable (see Fig. 1). 
Within the sequence of the synthetic peptide the percentage of identity 
between the members of the S100 family is 14% at maximum (2 ol 
14). We also performed blocking experiments in which calcyclin-
peptide or purified calcyclin was added to the incubation mixture. Nc 
signal could be detected within this control as shown in Fig. 4. When 
using unrelated peptides or SlOOa or β synthetic peptides insteac 
calcyclin staining was not affected (results not shown). 
The staining results of the melanocytic lesions are summarized ir 
Figs. 5 and 6. Since we observed a marked difference between junc­
tional and dermal parts of NN, CN, and thin PM, we estimated the 
percentage of staining cells and the intensity of staining in these 
compartments separately. No staining was observed in the junctional 
region of DN and CN, and hardly any staining was detected in NN 
(4%). However, in 11 of 37 cases of thin PM, staining in the junctional 
part was observed (30%). Staining was either weak (1 case) or mod­
erate (4 cases) in 1-5% of cells within a lesion, moderate (1 case) oi 
strong (1 case) in 10-25% of the cells, strong in 25-50% (2 cases) ol 
the cells, or strong in 50-75% of the melanocytic cells within a lesion 
(2 cases). Eleven of 20 NN showed a moderate to strong staining in 
the dermal part. Interestingly, the intensity of staining appeared to be 
higher toward the lower dermal part. In none of 22 DN, calcyclir 
protein could be detected. 
When comparing calcyclin expression in the dermal parts of thin 
and thick PM (see Fig. 6), a stronger staining is observed in thick PM 
(63% of thick PM showed strong staining compared to 18% of thir 
PM) and a significantly higher percentage (P = 0.04 using a non-
parametrical Mann-Whitlcy i/test) of staining cells (see Fig. 5). Only 
in 1 out of 19 cases of thick PM staining was absent, whereas 10 o] 
28 thin PM showed no expression in their dermal part. 
When classifying all PMs according to Clark levels corresponding 
to the invasive grade of melanoma, a significantly lower percentage oi 
staining cells was present in Clark II melanomas as compared tc 
melanomas with higher Clark levels [see Fig. 6; Ρ = 0.001 for Clark 
II versus higher levels (III-V), 0.007 for comparing Clark level II anc 
III, and 0.002 for comparing Clark level II and IV]. 
In 13 melanoma metastases various staining patterns were observée 
varying from a weak staining in a small percentage of cells to a strong 
staining in nearly all cells. Thirteen CN and 16 SN showed a moderate 
to strong staining, which was present in a very high percentage of the 
cells in the case of SN. SN were stained in a homogeneous manner 
Remarkably, in a number of CN and MM, nuclear staining was ob-
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Fig. 3. Northern blot analysis of calcyclin expres­
sion in various types of nevi: NN, DN, CN, 12 MM, 
and normal skin (SK). The pools of NN. DN, CN, and 
skin are described in "Materials and Methods." bach 
lane contains 10 μg of total RNA. Bottom, the control 
hybridization, using a ribosomal probe, kb. kilobascs 
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served besides the usual staining of the cytoplasm. Stained lesions 
from each type arc shown in Figs. 4 and 7. 
Expression of Calcyclin in Nonmelunocy tic Skin Tissue. Except 
for melanocytic cells, specific staining was also observed in other 
types of cells present in skin. A very high expression was detected in 
the epithelium of the hair follicle. Sebaceous glands, sweat glands, 
and fibroblasts also showed calcyclin staining; however, there were 
variations in the degree of staining. In particular, dermal dendrocytes 
present in stroma tissue between the melanocytic nests showed a very 
strong staining. Nerve bundles invariably showed a strong staining'. 
Blood vessel endothelium was stained in most but not in all cases. The 
specificity of these stainings was confirmed by blocking experiments 
as already described above (results not shown). 
DISCUSSION 
In previous experiments we demonstrated that calcyclin mRNA 
expression correlated with metastatic potential of human melanoma 
cell lines (6). In the current study, we extended this finding to xeno­
graft material of these cell lines. Both at the RNA and the protein 
level, calcyclin expression was highest in the high metastatic BLM 
and MV3 xenografts. A good correlation between RNA and protein 
levels could be established in all xenografts. 
When extending these experiments to human melanocytic lesions, 
we observed an elevated RNA expression in melanoma metastases as 
compared to several types of nevi and skin. For a number of mela­
noma metastases, we examined calcyclin expression at both the RNA 
and protein level. In most cases, elevated levels of RNA did not lead 
to a much higher expression at the protein level. During neoplastic 
progression, a loss of the link between RNA and protein obviously 
occurred. 
In terms of relevance for tumor progression, the transition of the 
radial growth phase to the vertical growth phase is very important, 
since invasion through the basal membrane and vertical growth en­
ables a melanoma to become metastatic. This transition is thought to 
occur between Clark level II and III. When examining calcyclin 
protein levels in a series of routinely processed lesions, two important 
observations can be made. A significant lower percentage of staining 
cells was observed in Clark II melanomas upon comparison to mela­
nomas with higher Clark levels, indicating that calcyclin expression in 
the dermal part is elevated during progression into the vertical growth 
phase which is also reflected by a stronger staining in a higher per­
centage of cells in thick PMs as compared to thin PMs. Secondly, the 
emergence of calcyclin expression in the junctional part of thin PMs 
is also associated with the malignant stages. Remarkably, dysplastic 
nevi did not show any expression at all. When focusing on the most 
important steps in melanocytic tumor progression (the progression 
from the precursor lesion into a PM in situ and the transition of radial 
into vertical growth phase of a PM) calcyclin can be considered a 
progression marker. Other progression markers also show expression 
in NN and melanoma but have a lower expression in DN, e.g., the 
α-chain of VLA-2 (18). The opposite has been described for histo-
compatability leukocyte class I antigens (14). Calcyclin expression in 
NN was preferentially present in the lower dermal part which would 
form a particular microenvironment; e.g., the reticular dermis is more 
densely packed and contains more type I collagen and lesser amounts 
of type HI than the papillary dermis (20). This, among other compo­
nents, might be of influence on the expression of calcyclin. Calcyclin 
expression in the junctional part of PM mighl reflect an autonomous 
change in the expression of the melanocytic cells themselves or an 
induced change in the microenvironment. 
In contrast to the absence of calcyclin protein in DN, tissue ho-
mogenates of DN did show mRNA expression. This apparent discrep­
ancy can at least partly be explained by the presence of several 
calcyclin-expressing structures, found within the dermis: hair fol­
licles; sebaceous glands; sweat glands; nerve bundles; fibroblasts; and 
-vit >;ш?Ъ »* ^ tSÄLsi •' ' - " ΐ ί • · 
Fig. 4. Calcyclin staining of nevocellular nevus (a) and blocking (b) by the addition of calcyclin-peptide to the incubation mixture (1(H) μ£/ηιΙ)(χ UK); hemuloxylin counterstaining). 
47 
CALCYCLIN IN MELANOCYTIC LESION5 
Nevocellular Nevi 
dannai pari 
% oí staining calls 
no staining ~ 
Primary Melanoma 
darmal part (thin) 
Primary Melanoma 
(thick) 
1-5 Л 
5-10 
10-25 9 
25-50 9 
SO-75 S±m 
75-100 £ • 
D 
0 20 40 Μ βΟ 
% of Isslons 
Congenital nevi 
darmal part 
% of staining colls 
20 40 M 80 100 
% of lesions 
Spitz nevi 
20 40 βΟ в0 100 
% of Itslens 
Melanoma Metastases 
20 40 во во 
% of lesions 
100 0 20 40 60 βΟ 100 
% of lésions 
20 40 60 80 100 
% of Isslons 
Intensity of staining 
тшшпіГі 
weak modérete strong 
Fig 5. Distribution of calcyclin slainuig in NN, Ihm PM, and CN (dermal part), ііікк PM, MM, and SN. Lesions which contained more lhan 1% of positively staining cells were 
scored as positive The percentage was based on melaoocylic cells only One particular thin PM showed a weak to moderate staining in 25-50% of the cells, but wilhin this lesion a 
small region was observed (representing 5-10% of ihe cells) with a strong sunning This lesion was marked as a moderately Stauung lesion Likewise, one particular congenital nevus 
showed a weak staining in mosl cells (50-75%), however, about Ю% showed a strong slaimog This lesion was also marked as a moderately staining lesion. 
blood vessels. Calcyclin was postulated as a marker for epithelial cells 
and fibroblasts (21). Here, wc show that there is expression in other 
cell types as well. A high RNA expression m mouse skin was also 
described by Guo et al. (5), which might be due to Ihe large number 
of hair follicles. A high expression in hair follicles was also reported 
by Wood et al. (22). 
Calcyclin was described as a growlh faclor-induciblc gene (2). 
Recently, calcyclin expression was reported to be elevated during 
corneal wound healing corresponding to a larger fraction of cells 
entering the Gt phase (23), indicating calcyclin would be a growth-
related gene. However, calcyclin expression was also induced during 
neuroblastoma cell differentiation (24). Another member of the S100 
family, SlOOß, has also been implied in growth and differentiation 
(25) Recently, S100/3 was reported to interact with Ihe tumor-sup-
pressor protein p53 in such a way that phosphorylation of pS3 was 
inhibited (26) Interactions have been described between SlOO-protein 
and annexin II and pll , the heavy and light chains of calpactin I (27, 
28) which is a major substrate for PKC. A link of calcyclin with PKC 
was also described (29), in which PKC inhibitor staurosporin could 
inhibit 4/3-phorbol-12-myristate-13-acelale-enhanced calcyclin ex-
pression. Like S100, calcyclin was reported lo interact with annexin II 
(30) and CAP-50, another member of the annexin-family (31). There-
fore, it becomes increasingly clear that calcyclin, like other members 
of Ihe SlOO-family, is involved in signal transduction. Since another 
microenvironment would also provide other signals, this might be an 
explanation for the differences in calcyclin expression between junc-
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Fig. 6 Distribution of calcyclin srainuig in primary melanomas (Clark levels II, HI, and Г ) Since only two Clark V PMs were present in our panel, these were not included in this 
Ggure These lesions showed a strong staining in 75-100% of the cells (1 case) and a moderate to strong staining in 25-50% of Ihe cells (1 case) Ten Dark II lesions, 21 Clark Ш 
lesions, and 14 Dark IV lesions were scored 
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Fig. 7. Calcyclin staining in a number of melanocyte lemons, a. DN (X 3(H)). Dark cells in the dermis represent melanophages. Dermal blood vessel endothelium is stained; b. 
junctional part of a thin PM (superficial spreading melanoma) ( x 500): с thin PM. dermal part (X 250); d. thick PM (nodular melanoma) (X 250); e. M M (X 300);/. SN (X 375). 
All lesions were hemotoxylin counterstained No positively staining melanocyte cells could be detected in a or b. 
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ïonal and papillary dermal parts of melanocyte lesions on one hand 
ind Ihe reticular part on the other 
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When screening a subtraction library for sequences that were 
specifically expressed in highly metastatic human melanoma 
cell lines, a cDNA clone was isolated encoding thymosin β-10. 
We found that expression of thymosin β-10 mRNA was associ­
ated with metastatic behavior of various human melanoma cell 
lines in nude mice. Furthermore, Northern blot analysis showed 
that also in freshly harvested human melanocyte lesions thymo­
sin β-10 was differentially expressed Although expression of 
thymosin β-10 was also examined in other non-melanoma 
model systems and materials, no clear relation could be estab­
lished with metastatic potential or malignancy. Therefore, we 
conclude that thymosin β-10 can be considered as a new 
progression marker for human cutaneous melanoma. 
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Thymosins were originally isolated from calf thymus and 
divided into 3 classes (α,β,-y) based on their isoelectric point 
(Low et al, 1981) The thymosin beta family comprises very 
small, highly conserved and acidic proteins Since thymosin β-4 
induces expression of the differentiation marker terminal 
deoxynucleotidyl transferase and was delected in thymus and 
peritoneal macrophages it was suggested that it was involved in 
some immunomodulatory function (Low et al, 1981) Later 
research showed that this is not likely to be the case, since very 
high levels of thymosins were found in other tissues as well 
(Hannappel et al, 1982, Erickson-Viilancn et al, 1983ft) No 
signal sequence could be found (Wodnar Tilipowicz et al, 
1984), indicating that thymosins arc probably not secreted, 
although a few reports have described the presence of thy 
mosins in blood and serum (Xu etat, 1982, Naylore/a/, 1984) 
In humans, thymosin β-10 is the minor β like peptide found in 
addition to thymosin β 4 (Frickson Vntaancn et al, 1983η) 
Most studies have focused on thymosin β 4, which has been 
described as a G actin binding protein in human blood 
platelets (Safer et al, 1991) Thymosin β 10 is less character­
ized and has been related to cell growth and proliferation (Lin 
and Mornson-Bogorad, 1990) 
Here we describe the isolation of thymosin β-10 as a 
differentially expressed cDNA clone when comparing a highly 
vs a sporadically metastatic human melanoma cell line in nude 
mice Applying the differential hybridization technique, using 
xenograft material derived from 2 subsequent stages of a 
primary melanoma of one patient, resulted in the isolation of 
calcyclin and other clones whose expression correlated with 
metastatic potential in nude mice (Weterman et al, 1992) 
Since it would be very useful for diagnostic purposes to obtain 
clones that would mark the transition between non-mctastasiz-
lng and metastasizing mclanoevtic lesions, we chose for a 
model system of 2 cell lines derived from the same melanoma 
metastasis, one of which appeared to be a highly metastatic 
variant in nude mice (van Muijen et al 1991ft) Our results 
show that thymosin β 10 expression is associated with progrès 
Sion of human cutaneous melanoma 
MATERIAL AND METHODS 
Melanoma cell lines and xenografts 
Human melanoma cell lines 1F6, 530, M14, Mcl57, BLM 
(van Muijcne/ al, 1991e), MV3 (van Muijene/я/, 1991ft), and 
MV1 (van Muijen el al, 1991c) were grown in Dulbecco's 
modified Fagle's medium supplemented with 10% FCS, glula-
min (2 mM), penicillin G (100 units/ml), streptomycin (100 
μg/ml), and pyruvate (1 mM) Aliquots were trypsinized and 
frozen at -70°C for RNA extractions MV1 and MV3 were 
derived from the same tumor after 1 and 3 passages respec­
tively in nude mite (van Muijen et al, 1991c) The MVI cells 
used for these experiments represent the lower metastatic 
phenotype, giving rise to spontaneous metastases in about 10% 
of the tumor bearing animals MV3 cells produce spontaneous 
metastases in approximately 90% of the tumor-bearing ani­
mals In our panel of cell lines, 1F6, 530, M14 and Mcl57 
represent the non or low-mctastasizing cell lines, whereas 
BLM and MV3 represent the highly metastatic phenotype (van 
Muijcntre/, 1991a) Approximately 1-2 χ IO6 cells were used 
for s e inoculation into nude mice (nulnu BALB/c, Labora­
tory Breeding and Research Center, Bomholtgaard, Ry, Den­
mark) In one case, when we used a batch of MVI cells that 
had been cultured longer 80% of the tumor-bearing animals 
developed metastases This material used for the production of 
xenograft tumors was marked as MVI* 
Human material 
After excision, large parts of melanoma metastases were 
immediately frozen at -70°C For RNA isolations from 
common ncvocellular nevi, dvsplastic nevi or congenital nevi a 
representative slice was taken Most of the skin surrounding 
these lesions was cut olí before freezing the material in liquid 
nitrogen The remainder was processed for conventional 
histopathology When using this material or normal skin tissue, 
6 to 22 lesions of 6 to 17 patients were pooled in order to obtain 
enough material Melanoma metastases were processed indi-
vidually and were taken from patients other than those from 
whom the nevi were removed 
A Northern blot containing RNA from uterus smooth-
muscle tissue, leiomyomas, leiomyosarcomas and adjacent 
normal smooth-muscle tissue was generally provided to us by 
Dr Τ Gloudemans (Department of Physiological Chemistry, 
University Hospital of Utrecht) 
Renal-carcmoma model system 
Cell pellets and xenograft lesions derived from renal carcino­
mas were generously provided by Dr II Romijn (Department 
of Urology, Erasmus University Rotterdam) RC2 and RC21 
arc weakly metastatic cell lines after orthotopic inoculation 
into nude mice RC43 is a highly metastatic cell line, as are cell 
lines that were derived from metastases produced after ortho­
topic inoculation of RC43 cells into nude mice Cell lines were 
derived from metastases in the liver (MLi), spleen, (MSp), 
diaphragm (MDi) and bowels (MBo) Tumors arising after s с 
'To whom correspondence and reprint requests should be 
addressed 
Abbreviations cDNA complementary DNA TPA 12 О letradec 
anoylphorbol 13 acetate DMSO dimelhylsulfoxide NGÏ* nerve 
growth factor SDS sodium dodecyl sulphate EDTA ethylcnediamine 
tetraacettc acid 
Received August 3 1992 and in revised form September 30,1992 
53 
inoculation of these sub-lines into nude mice were used for 
RNA extractions No metastases were observed after sc 
inoculation 
RNA isolation and Northern blot analysts 
Total RNA was isolated using the lithium urea procedure as 
described by Auffray and Rougeon (1980) Oligodeoxythymi 
dine selections were performed using oligodcoxylhymidine 
columns (type II Collaborative Research, Bedford, MA) Ten 
to twenty micrograms of total RNA were glyoxylatcd, size 
fractionated on 1% agarose gels and blotted on Ilybond N-plus 
(Amersham, Aylesbury, UK) according to the procedure 
recommended by the manufacturer To reconfirm that equal 
amounts were loaded ш each lane, the blots were afterwards 
hybridized to 28S or 18S ribosomal probes 
Construction ofcDNA libraries 
cDNA libraries were constructed from 5 μg of oligodeoxythy-
midine selected RNA using a cDNA cloning kit (Invitrogen, 
San Diego, CA) 
Subtraction and differential hybridization 
For the production of the subtracted library a subtractor kit 
was used (Invitrogen) Basically single-stranded DNA was 
isolated from both the MV1 and the MV3 library MV1 cDNA 
was photobiotinyldted and hybridized in excess to MV3 cDNA 
sequences, followed by removal of the biotinvlated sequences 
by selective precipitation (using ammonium acetate) and 
afterwards additional phenol extraction MV3 specific se­
quences were converted into double stranded cDNA and 
transformed into £ co/iINVlaF cells (Invitrogen) 
Differential screening was performed in duplicate Four 
replicas were made of each plate The firs! and third replica 
»ere hybridized to an MVl-denved probe, the second and 
fourth were screened with an MV3 derived probe Equal 
amounts of counts and probes of comparable specific activity 
were used for this purpose Hybridization of the filters was 
performed in 5 χ SSC, 50% formamide, 10 mM sodium 
phosphate, 1 x Dennhardt, 5 mM EDTA, in the presence of 
denatured herring sperm DNA at 42°C Filters were washed in 
a stringent manner, using decreasing salt concentrations (2 to 
0 1 X SSC/0 V/c SDS at 42 lo 65°C)~ Clones corresponding to 
a marked difference in expression after comparison of the 
resulting autoradiographs were further characterized 
DNA probes and hybndization 
Probes derived from MV1 and MV3 RNA were constructed 
as described (Weterman et al, 1992) DNA probes were 
radiolabeled using the multiprime labeling method as de­
scribed by Amersham The hybndization of Northern blots was 
performed according to the method of Church and Gilbert 
(1984) with the addition of 0 1 mg denatured herring sperm 
DNA/ml of hybridization mixture 
DNA sequencing and computer analysis 
DNA fragments were ligated into M13mpl8, M13mpl9 or 
pGEM vectors and sequenced according to the didcoxy method 
as described by Sanger et al (1980) Sequences were deter­
mined from both strands of the cloned cDNAs Searches for 
known sequences were performed using the Genbank and 
EMBO databases (Pearson and Lipman, 1988) 
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Fir.LRE 1 - cDNA sequence of human melanoma thymosin β-10 Differences with the published sequence (McCreary et al, 1988) are 
marked by asterisks 
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RESULTS 
Isolation of a thymosin ß-10 cDNA dorn· 
A subtraction library was constructed from RNA of the 
highly metastatic human melanoma MV3 cell line and the 
less-mctastatic MV1 cell line. To evaluate the enrichment of 
М З-specific sequences, several cDNA clones were picked at 
random, radiolabeled and hybridized to Northern blots contain­
ing MVI and MV3 RNA. This led to the isolation of some 
weakly differentially expressed cDNA clones, one MV3-
specific clone and one MV1-specific clone. When the MV3-
specific clone was tested on a panel of human melanoma cell 
lines with different metastatic behavior it did not correlate 
with the metastatic behavior of other human melanoma cell 
lines, except for MV3 and MV1 (results not shown). To 
increase the number of М З-specific clones, part of this library 
(5000 recombinant clones) was differentially screened using 
MV1 - and M З-cDNA probes. 
One of the clones isolated in this way. designated pMW7. 
showed a marked difference in expression between the MV1 
and the MV3 cell lines and was chosen for further characteriza­
tion. 
Sequence analysis revealed a near identity to thymosin ß-10. 
Only a few minor changes were noted in comparison with the 
first published sequence (McCreary et al.. 1488). none within 
the coding region. We find an additional ОСЛЛС (positions 1 
to 5), and another sequence (positions 449 to 453) just before 
the poly-A tail (TGGCATGGCAn instead of TGGCAn) as 
illustrated in Figure 1. The changes at position 312.315.320 (an 
additional C) and 403 (G instead of A) were also described by 
Halle/al. (1990). 
Expression of thymosin-ß-10 mRNA in a hitman melanoma 
model system 
The expression of thymosin ß-10 was examined in a panel of 
human melanoma cell lines with different metastatic potential 
in nude mice. The expression was highest in the 2 highly 
metastasizing cell lines BLM and MV3. Upon comparison with 
the weakly or non-mctastasizing cell lines 1F6. 530. M14 and 
Mel57 (Fig. 2) the elevation was estimated to be 10 to 20 fold. 
The mRNA expression in s.c. xenograft lesions of these cell 
lines showed a pattern similar to that of the cell lines: 
expression was highest in the BLM and MV3 xenografts and a 
marked difference in expression between these and xenograft 
lesions from the other cell lines except for MV1* was observed, 
although the difference in expression with the xenografts 
derived from the other cell lines was reduced when compared 
with the differences found between the same cell lines (the 
difference in expression was estimated to be 4- to 5-fold). A 
variant of the MV1, which produced spontaneous metastases 
in nearly all mice, designated MV1*. was used in this experi-
ment to obtain xenograft material. Thymosin ß-10 expression 
changed likewise to an elevated level in this MV1-variant 
(Fig.3). 
Thymosin ß-10 as a possible progression marker for hitman 
cutaneous melanoma 
Since our final goal was to isolate new progression markers 
for human cutaneous melanoma, a Northern blot was screened 
which contained RNA isolated from several types of melano-
cyte nevi (common nevi, dysplastic nevi and congenital nevi) 
and melanoma metastases (Fig. 4). RNA preparations from 
melanoma metastases were derived from one patient each, the 
lanes loaded with nevus RNA contain pooled material of 6 to 
22 lesions derived from 6 to 17 persons. The overall expression 
was higher in the melanoma metastases than in the benign 
mclanocytic lesions tested (stimulation of expression was 
estimated to be a factor of 5 to 10). Congenital nevi were 
obtained from 6 persons and showed an elevated expression of 
2- to 3-fold. As a control, normal skin was used, in which also 
low expression was observed (about 3- to 5-fold lower than the 
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Fici'RE 2 - Northern blot analysis of several human melanoma 
cell lines; 10 μg of total RNA were loaded in each lane. Lane A. 
1F6: lane B. 530; lane С. M14: lane D. Mel57: lane E. BLM; lane 
F. MV3; and lane G. MV1. The blot was hybridized to radio­
labeled thymosin ß-10. The molecular-weight marker was XDNA 
digested with restriction enzvme Hindlll. Bottom: control hybrid-
ization using a 28S ribosomal probe 
M (kb) 
4.4 
2.3_ 
2 .0 . 
0.6. 
28S . 
rRNA 
FIGURE i - Northern blot analysis of several melanoma xeno-
grafts in nude mice; 20 μg of total RNA were loaded in each lane. 
Lane A. 1F6; lane B. 530; lane C, M14; lane D. Mel57; lane E. 
BLM; lane F. MV3; and lane G. MV1 *. The blot was hybridized to 
radiolabeled thymosin ß-10. The molecular-weight marker was 
XDNA digested with restriction enzyme Hindlll. Bottom: control 
hybridization using 28S ribosomal RNA as a molecular probe. 
expression in nevi), visible only after a longer exposure of the 
film. 
Expression of thymosin β-10 mRNA in other organs and model 
systems 
For further characterization, a Northern blot containing 
RNA of several rat organs was screened, using thymosin ß-10 
as a molecular probe. Thymosin ß-10 mRNA was detected in 
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FIGURE 4 - Northern blot analysis of several human melanocyte lesions; 10 μg of total RNA were loaded in each lane. NN, naevus 
naevocellularis (common nevi; the first lane contains RNA isolated from 17 lesions of 10 patients, the second lane contains RNA isolated 
from 9 lesions of 7 patients); DN, dysplastic nevi (22 lesions from 17 patients); CN, congenital nevi (ft lesions from ft patients); MM, 
melanoma metastasis; SK, skin (8 lesions, 7 patients). The molecular-weight marker was XDNA digested with restriction enzyme 
Hindlll. Bottom: a longer exposure shows that there is some expression in skin. Control hybridization was performed using a 18S 
ribosomal probe. 
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FIGURE 5 - Northern blot analysis of thymosin (3-10 expression in several rat organs; 10 μg of total RNA were loaded in each lane. 
Bottom: control hybridisation using a 28S ribosomal probe. The molecular-weight marker was XDNA digested with restriction enzyme 
Hindin. 
several rat organs (Fig. 5). In the testes, 2 mRNAs were 
detected of about 600 and 750 base-pairs in length. The 600 
base-pair mRNA was seen in the lanes containing rat spleen, 
prostate, lung, bladder and intestinal RNA. 
Since it would be interesting to know whether thymosin β-10 
is also differentially expressed in other types of cancer or has a 
preferential expression for melanoma, thymosin β-10 was also 
hybridized to Northern blots containing several cell lines and 
xenografts of a human renal-carcinoma model system, and 
patient material of a number of leiomyosarcomas and leiomyo­
mas. The renal-carcinoma model system revealed a difference 
in the level of expression between the 2 non-metastasizing or 
weakly metastasizing cell lines (RC2 and RC21) (Fig. 6) and 
the 2 more highly metastasizing cell lines (RC43 and MSp). 
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RC2 RC21 RC43 MSp RC2x RC21x RC43x Müx MSpx MDix MBox 
28S rRNA 
FK;LRL 6 - Northern blot analysis of thymosin β-10 expression in a renal-carcinoma model s\stcm. The lirst 4 Lines contain 12.5 μg of 
total RNA from cell lines RC2. RC21. RC43. and RC43MSp. The other lanes contain xenograft RNA from RC2. RC'21. RC43. 
RC43MIÌ. RC'43MSp, RC43MDÌ, and RC43MBO. The molecular-weight marker was ADNA digested with restriction enzyme Hindlll. 
Bottom: control hybridization using a 28S ribosomal RNA probe. 
U3 IM AOJI LM1 ADJ2 LM2 ADJ3 LM3 ADJ LM51LMS2 LMS3 LMS4 LM55LM56LM57 
FlüLRE 7 - Northern blot analysis of thymosin β-10 expression in several human smooth-muscle-derived tumors and adjacent normal 
smooth-muscle tissue. UT, uterus; ADJ, smooth-muscle tissue adjacent to a leiomyoma or leiomyosarcoma. The first lane of each pair 
contains the normal tissue, the second lane contains the leiomyoma or leiomyosarcoma. LM. leiomyoma: LMS. leiomyosarcoma. The last 
6 lanes on the right contain only leiomyosarcomas, without showing adjacent smooth-muscle tissue. For size estimation, the 2SS and 18S 
ribosomal bands are indicated. Bottom: control hybridization using a 28S ribosomal probe. 
However, these differences were not detected in the s.c. 
xenograft lesions of these same cell lines and other cell lines 
(MSp, Ml.i. MDi, and M13o) derived from the metastases 
formed after orthotopic inoculation. 
Northern blot analysis of smooth-musclc-dcrivcd tumors 
showed the highest expression in leiomyosarcomas, but not in 
all (Fig. 7). In normal smooth-muscle tissue no consistent 
pattern of thymosin β-10 expression was observed. 
DIM I SSKIN 
Differential screening of part of a MV3-MV1 subtraction 
library led to the isolation of thymosin β-10 as a potential 
progression marker for human cutaneous melanoma. North­
ern blot analysis revealed a marked difference in expression 
both in cell lines and in xenografts when comparing highly i.V. 
weakly metastasizing cell lines or the xenograft lesions derived 
from these. 
The thymosin ß-family comprises small peptides with a 
function as yet unknown. Thymosin ß-4 was also isolated as a 
differentially expressed clone upon comparison of more or less 
differentiated ostcoblast-like cells (Atkinson et ai, 1990), 
intcrfcron-treated neuroblastoma cells (Friedman et ai, 1984), 
lymphoid cells (McMahon et ai. 1986), or NGF-treated PC12 
cells (Leonard et ai, 1987). Elevation of thymosin ß-4 messen-
ger levels was observed in more differentiated or treated cells 
as compared to less differentiated or untreated cells. Thymosin 
ß-4 has been described as a G-actin-binding protein in blood 
platelets (Safer et ai. 1991) and thus might be important in 
regulation of actin-polymerization in many cell types (Sanders 
et ai. 1992). Since thymosin levels are very high, a link with the 
cytoskcleton has been made before (Wodnar-Filipowiczef я/.. 
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1984) Bolh thymosin ß-4 and β-10 levels have been described 
as being higher in ncopljstic lesions than in normal tissue 
Thymosin β-10 in particular might function as j progression 
marker for renal carcinoma (Hall, 19916) We find an elevation 
of thymosin β 10 mRNA expression in the more metastatic 
renal-carcinoma cell lines, however, the xenografts of these 
cell lines do not show a corresponding pattern This could be 
explained bv the method of inoculation, since s c injection 
would create an artificial environment for renal tumors 
Thymosin ß-10 expression was found to be high in tissues 
exhibiting cell proliferation and was identified as a highly 
developmental^ regulated sequence in rat brain (Lin and 
Mornson-Bogorad, 1990) We have shown that the least 
metastasizing cell lines of the renal-carcinoma model system 
have the lowest expression, while these cells grow faster than 
the metastatic ones In this case, no correlation can be 
detected with cell growth Thymosin β-10 was also suggested as 
being involved in the division and migration of some, but not 
all, neuronal populations (Lin and Mornson-Bogorad. 1990) 
In neuroblastoma cells, thymosin ß-10 is reported to be 
modulated by retinole acid and retinole acid receptor (Hall, 
1992) 
For further characterization, thymosin ß-10 expression was 
examined in several rat organs and other tumor model systems 
Expression of thymosin ß-10 was detected in various rat organs 
(spleen, testis, prostate, lung, bladder and the intestines) 
Lxpression was highest in testis A larger mRNA appeared, 
which was also described by Lin and Mornson-Bogorad (Lin 
and Mornson-Bogorad, 1990) Except for the thvmus, our 
results arc in agreement with the tissue distribution described 
This discrepancy could be caused bv difTcrcnt ages of the 
animals used for excision of the organs Additionally, we hnd a 
relatively high expression in prostate, bladder and the inles 
tines 
In human lesions derived from smooth-muscle (issue, expres-
sion in some of the more aggressive leiomyosarcomas was 
slightly elevated as compared to the leiomyomas Since this is 
only a slight elevation and is not present in all Iciomyosarco 
mas tested, it is unclear whether thymosin ß-10 expression 
could play a role in the progression of these tumors 
Northern blot analysis of human melanocyte lesions showed 
that the findings of our model system could be extended to 
human material Although these results do not necessarily 
predict protein data, thymosin ß-10 mRNA expression in nevi 
and dysplaslic nevi was 5 to 10 told lower than m most of the 
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contained some normal skin (issue whereas most of the 
tumors consist mainly of tumor tissue and this could lead to a 
lower level of expression assuming that in skin no thymosin 
ß-10 expression would be present As a control, normal skin 
RNA, containing both RNA from fibroblasts and kcratinocytes 
in an amount comparable to the tissue surrounding the nevi, 
was loaded onto trie same gel Although the amount of RNA 
was lower than in the other lanes, longer exposure showed a 
weak signal in these lanes indicating that expression is present 
in skin Moreover, we think (hat although (here was skin tissue 
present in these lesions, most of the RNA was derived from 
nevus RNA, since this tissue consists of fewer extracellular 
components than normal skin The yield of RNA extractions 
from skin was lower than the amount of RNA isolated from 
nevi, even when far more starting material was used 
Since melanocytes are of neuroectodermal ongin, the 
previously reported high expression of thymosin ß-10 during 
neuro-cmbryogenesis is interesting, although its function in 
this process remains to be defined (Lin and Mornson-
Bogorad, 1990 Hall, 1991o) In view of the high homology 
between members of the thymosin-bcta family, it is tempting to 
speculate that thymosin ß-10 would also be involved in some 
was with the cvtoskclcton as described for thymosin ß-4 It has 
already been suggested that thymosin ß-10 is also important in 
the polymerization of (he aclin cytoskelclon in fibroblasts (Lin 
and Mornson-Bogorad, 1992) Since motility and adhesion 
processes are extremely important in tumor progression, the 
role of thymosin ß-10 in melanoma progression is particularly 
interesting 
ACKNOWLEDGEMENTS 
We thank Dr Τ Gloudcmans for generously providing the 
smooth muscle-dcrivcd tumor and normal smooth muscle 
tissue RNAs Dr H Romijn for providing the material for 
RNA isolations of the renal carcinoma model system Dr R 
Koopman and Dr Τ Wobbes for providing human melano­
cyte lesions and Mr О Stoopcn. Mr N Ayubi, Ms I 
Cornelissen and Mr К Jansen lor their technical assistance 
This work was supported by the Dutch Cancer Foundation, 
grant NUKC 89 08 
late thymosin β 10 gene expression in transfectcd neuroblastoma cells 
Cell mol Neumbtol 12,45 58(1992) 
Нлп AK 111 MPSi TAD J and MORGAN, J I Thymosin ß-10 levels in 
developing human hrain and its regulation by retinole acid in the 
HIB 10neuroblastoma Mol BramRes 8,129-115(1990) 
HANNAPPLI, Ε Χι C-I MORGAN J HEMPSTEAD J and 
HOKICKLR BL Thymosin β4. a ubiquitous peptide in ral and mouse 
tissues Proc nat Acad Sci (Wash ) 79, 2172-2175 (1982) 
LEONARD D G B ZIFF fcB and GRILNT LA Identification and 
characterization of mRNAs regulated bv nerve growth factor in PC12 
cells Vol cell Biol 7,3156-3167(1987) 
LIN, S С and MORRISON BOOORAD, M Developmental expression of 
mRNAs encoding (hymosins ß-4 and β 10 in rat brain and other 
tissues J mol \eurosa 2,35^)4 (1990) 
I IN, S С and MORRISON BÍX.ORAD M Cloning and characterization 
of a testis specitu. thymosin β К) «.DNA expression in posi melone 
male germ cells J huil С hem 2*6,2П47-2.1151 ( 1992) 
Low, TL К, Hi S К and GOLOSI LIN AL Complete amino acid 
sequence of bovine thymosin ß-4 a thvmic hormone that induces 
terminal deoxvdinucleoiidvl transferase activity in thymocyte popula 
lions Л и nat Acad Sci Wa%h) 78, 1162-1166(1981) 
MCCRLARY, V, KARTHA S . Πι ι u G I and Товлск, F G , Sequence 
RFFERENCES 
58 
of a human kidney cDNA clone encoding thymosin β 10 Biochem 
Bioph\s Res Commun, 152,862-866(1988) 
МсМлноч M , STARK, G R and KFRR 1 M , Interferon induced gene 
»pression in wild-type and interferon-resistant human lymphoid 
(Daudl) cells J Virol 57,162-366 (1986) 
NAYLOR, Ρ H , MCCLURE, J E , SPANùfcLO, В L, Low, Τ L К and 
Gol DSTEIN, A L, Immunochemical studies on thymosin, radioimmu­
noassay of thymosin β-4 Immunopharmacohfry, 7,9-16(1984) 
PFARSON, W R and LIPMAN, D J , Improved tools for biological 
sequence comparison Proc nat Acad Sci (Wash ) , 85, 2444-2448 
(1988) 
SAFER, D , ELZINCÎA, M and NACHMIAS, V Τ , Thymosin β-4 and Fx, 
an actin-5equestenng peptide are indistinguishable J biol Chem, 266, 
»029-4032(1991) 
SANDERS, M С , GOLDSTEIN, A L. and WANG, Y -L, Thymosin β4 (Fx 
peptide) is a potent regulator of aclin polymerization in living cells 
Proc nat Acad Sci (Wash ), 89,467K-4682 (1992) 
SANGLH, F, COULSON, A R , BARRED , В G, SMITH, A J H and ROE, 
Β A , Cloning in single-stranded bacteriophage as an aid to rapid 
sequencing J mot Biol 143,161-178(1980) 
VAN MUIJEN, G Ν Ρ . CORNLLISSFN, L.M A H JANSFN, Γ Ρ J , FlCi-
DOR. С G, JOHNSON, J Ρ , BROFCKER, Ε -Β and RUITLR, DJ , Antigen 
expression of metastasizing and non-metastasizmg melanoma cells 
xenografted to nude mice Clin exp Metastasis, 9,259-272 (1991a) 
VAS MUIJFN, G Ν Ρ, JANSEN, С Ρ J , CORNELISSLN L M A II, SMLLTS, 
D F С M , BFCK, J L M and RUITER, D J , Establishment and charac­
terization of a human melanoma cell line (MV3) which is highly 
metastatic in nude mice Int J Cancer 41,85-91 (1991b) 
VAN MUIJFN, G Ν Ρ . WbrLRMAN. M A J , QLAX. Ρ Η A , VERHLIJLN, 
J H and RUITI R, D J , Phenotypic profile of two melanoma cell lines 
isolated from the same patient with different metastatic behavior in 
nude mice Proc Amer Ass Cancer Ret, 32, 62 (1991c) 
WbTT-RVIAN. M A J , S T O O P F N , G M , VAN MUIJLN, G N P , KUZNICKI, 
J . RUITLR, D J and BLOEMERS, Η Ρ J , Expression of calcyclin in 
human melanoma cell lines correlates with metastatic behavior in 
nude mice Cancer Res, 52,1291-1296 (1992) 
WODNAR-FlLIPOWirZ, A , GlJBLER. U . FuRUICHI, Y . RICHARDSON, 
M , NowoswiAl, E F . POOMAN, M S and HORFCKFR, В L, Cloning 
and sequence analysis of cDNA for rat spleen thymosin β 4 Proc nat 
Acad Sci (Wash) 81,2295-2297(1984) 
Xu, G J , HANNAPPEL, Γ , MORGAN, J . Hi MPSTEAD, J and 
HORECKI R, В L Synthesis of thymosin β 4 by peritoneal macrophages 
and adherent cells Proc nal Acad Sci (Wash) 79,4006-4009(1982) 
59 

Chapter S 
A novel gene, nmb, is expressed in low-metastatic human melanoma 
cell lines and xenografts 
Marian A.J. We temían, Nasser Ajubi, Irma M.R. van Din ter, Winfried G.J. Degen, 
Goos N.P. van Muijen, Henri P.J. BLoemers, and Dirk J. Ruiter 
Submitted for publication 

A novel gene, nmb, is expressed in low-metastaüc human melanoma cell lines 
and xenografts 
Marian A. J. Weterman', Nasser Ajubi', Irma M.R. van Dimer', Winfried G.J. Degen1, Goos Ν. 
P. van Muijen2, Dirk J. Ruiter2, and Henri P. J. Bloemers'. 
Departments of Biochemistry' and Pathology2, University of Nijmegen, P. O. Box 9101, 6500 HB 
Nijmegen, the Netherlands. 
ABSTRACT 
From a subtractive cDNA library, several cDNA clones were isolated showing differential 
expression between high- and low-metastatic human melanoma cell lines. One of them, 
designated nmb, showed preferential expression in the low-metastatic cell lines and was 
chosen for further characterization. Sequence analysis revealed that this clone represents a 
novel gene, encoding a putative transmembrane glycoprotein, showing the highest homology 
to the precursor of pMEL17, a melanocyte-specific protein, nmb RNA expression was absent 
in most tumor cell lines tested and not restricted to the melanocyte lineage. Transfection of a 
partial nmb cDNA into a highly metastatic melanoma cell line (BLM) resulted in two of three 
transfectants in slower subcutaneous tumor growth and in one of three transfectants in 
reduction of the potential for spontaneous metastasis in nude mice. 
INTRODUCTION 
Melanocyte tumor progression is thought to evolve through several distinct stages from normal 
melanocytes into highly invasive melanomas capable of metastasis (1,2). Monoclonal antibodies 
have been prepared recognizing antigens with a preferential expression in one or a few stages of 
this process. Many of these molecules have been cloned and represent mostly adhesion molecules 
or growth factor receptors (3-5). Another approach, using the differential and subtraction 
hybridization techniques, led to the isolation of calcyclin (6) and thymosin β-10 (7) as potential 
progression markers for cutaneous melanoma. From a clinical point of view such markers as 
indicators of metastatic potential would be very useful. 
Although many markers have been isolated until now, it is useful to obtain a large panel of 
these markers, since a single marker or a few markers often show overlapping expression between 
benign and malignant stages. Many proteins that are upregulated during progression are also 
important in the normal physiology of the cell. Thus, discrimination can only be achieved when 
using a large panel of markers. The study of single markers is relevant, since it can provide us 
with a better insight in the process of tumor progression. 
cDNA clones which are expressed only in non- or low-metastatic cell lines or tumors, are 
candidates for tumor suppressor genes. In the field of melanoma research, nm23 was isolated 
upon comparison of high and low-metastatic murine melanoma cell lines (8). Although expression 
in nevocellular nevi was lower than in melanomas, nm23 expression in melanomas curiously 
showed an inverse correlation with disease progression (9). 
p53, another potential tumor suppressor gene, was originally reported to be mutated in a very 
large percentage of melanoma lesions (10). However, later reports showed mutations in p53 only 
in a small percentage of melanoma cell lines (11-13). Immunohistochemical studies reported most 
staining cells in melanoma metastases indicating that p53 mutations appear in a late stage of 
melanocyte progression (14,15). 
In an attempt to describe a subtraction library, we isolated several differentially expressed 
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cDNAs two of which are expressed only in low-metastatic cell lines and corresponding xenografts 
and appear to represent novel genes. In this study, we describe the characterization of one of 
them. 
MATERIALS AND METHODS 
Cell lines and xenografts. Human melanoma cell lines 1F6, 530, M14, Mel57, BLM (22), 
MV3 (23), and MV1 (24) were cultured as described before (18). MV1 and MV3 were derived 
from the same melanoma lesion after one and three passages in nude mice respectively (24). The 
MV1 cells used for these experiments represent the lower metastatic phenotype, giving rise to 
spontaneous metastases in about 10% of the tumor-bearing animals. MV3 cells produce 
spontaneous metastases in approximately 90% of the tumor-bearing animals. In this panel of cell 
lines, 1F6, 530, M14 and Mel57 are low-metastasizing cell lines, whereas BLM and MV3 
represent the highly-metastatic phenotype (22). Approximately 3x10" cells were used for 
s.c.inoculation into nude mice (nu/пи BALB/c; Laboratory Breeding and Research Center, 
Bomholtgaard, Ry, Denmark). A Northern blot containing total RNA of various cell lines was 
generously provided to us by Dr. P. Quax (Gaubius Institute IVVO, TNO, Leiden, the 
Netherlands). It contained RNA from: Bowes melanoma, HT1080 fibrosarcoma, Hela NIBSC and 
Hela S3 cervix carcinoma, MCF7 mammary carcinoma, A431 epidermoid carcinoma, Colo205, 
CaCo2, HT29, SW620, and SW480 colon carcinoma, KatoIII, and HGT-1 gastric carcinoma, 
HepG2 hepatoma, K562, U937 DK, and HL60 myeloid leukemia cell lines, and HS766T pancreas 
carcinoma cell lines. Human renal carcinoma cell lines were generously provided by Dr. J. 
Romijn (Dept. of Urology, Erasmus University Rotterdam, the Netherlands) and all derived from 
the same patient (7). Rat organs that were used for a Northern blot were: spleen, brain, liver, 
heart, muscle, kidney, testes, thymus, prostate, lung, bladder, intestines, and stomach. 
Human tissues. After excision, large parts of melanoma metastases were immediately frozen in 
liquid nitrogen and stored at -80°C. Melanoma metastases were processed individually and were 
taken from other patients than those from whom nevi were removed. For RNA isolations from 
common nevocellular nevi, dysplastic nevi (atypical nevi) or congenital nevi a representative slice 
was taken. Most of the skin surrounding these lesions was cut off before freezing the material in 
liquid nitrogen. The remainder was processed for conventional histopathology. Dr. R. Koopman 
generously collaborated in obtaining fresh human material. It is guaranteed that this procedure did 
not hamper diagnosis. When using nevi or normal skin tissue, 6 to 22 lesions of 6 to 17 patients 
were pooled in order to obtain enough material. A Northern blot containing smooth muscle-
derived tumors (leiomyomas and leiomyosarcomas) and normal adjacent and uterus tissue was 
generously provided by Dr. Τ Gloudemans (Dept. of Physiol. Chemistry, University of Utrecht, 
the Netherlands). 
RNA isolation and Northern blot analysis. Total RNA was isolated as described by Auffray 
and Rougeon (25). Oligo-deoxythymidine-selections were performed using oligo-deoxythymidine-
columns (type II, Coll. Research, Bedford, Massachusetts). 10 μg of total RNA were blotted on 
Hybond N-plus (Amersham, England) according to the procedure recommended by the 
manufacturer, after glyoxylation (26) and size fractionation on 1% agarose gels. To reconfirm 
equal loading the blots were hybridized afterwards to ribosomal RNA probes. 
Construction of cDNA and subtraction libraries. cDNA libraries were constructed from 5 μ% 
of oligodeoxythymidine selected RNA using a cDNA cloning kit (Invitrogen Corp., San Diego, 
CA). For the production of the subtracted library a subtractor kit was used (Invitrogen Corp., San 
Diego, CA). Construction was performed as described before (7). 
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Hybridization. DNA probes were radiolabeled using the multiprime labeling method as 
described by Amersham. Hybridizations of cDNA libraries were performed as described (7). The 
hybridizations of Northern blots were performed according to the method of Church and Gilbert 
(27) with the addition of 0.1 mg denatured herring sperm DNA/ml of hybridization mixture. 
Hybridization of Southern blots was carried out as described by the manufacturer (Amersham, 
England). Lower stringent conditions were obtained by lowering the temperature for hybridization 
and washes up to IS °C below the optimal temperature. 
DNA sequencing and computer analysis. A set of deletion clones was constructed from cDNA 
inserts longer than 400-500 bp using the erase-a-base system (Promega, Madison, Wisconsin). 
DNA fragments were ligated into M13mpl8, M13mpl9 , pTZ or pGEM vectors and sequenced 
according to the dideoxy method as described by Sanger et al. (28). Sequences were determined 
from both strands of the cloned cDNAs. The sequence of PCR products were determined using 
three independent PCR reactions. Searches for known sequences were performed using the 
Genbank and EMBO databases (29,30). Searches for motifs, alignments, and structure predictions 
were performed using the CAMMSA programs MOTIFS, PILEUP, CLUSTAL V, BESTFIT, 
PEPTIDESTRUCTURE, PLOTSTRUCTURE, and MEMBRANE PROPENSITY programs which 
are all part of the Wisconsin Package V 7.0 (29). 
Primer extension. A 149 bp Avall-Ndel restriction fragment (located at position 331-480) was 
used as a primer. The extension reaction using reverse transcriptase was based on standard 
protocols (31). 250 ng of ds cDNA was end labeled using γ-ΜΡ-ΑΤΡ (Amersham)(specific activity 
of ЗЛО7 cpmVg) and 4.103 cpm were added to 10 μg of oligo(-deoxythymidine)-selected MV1 
RNA. After denaturation for 10 min. at 85 °C annealing was performed at 45 °C overnight. The 
extension reaction was performed at 37 °C for two hrs. using Moloney reverse tranciptase (BRL, 
Life technologies Inc., Grand Island, NY), purified, and analyzed on a sequencing gel containing 
sequence reactions as a size marker for the length of the extension products. 
Cloning of the 5' end of nmb cDNA The 5' end of nmb was cloned using the amplifinder kit 
(Clontech, Palo Alto, California). Basically, after oligo-deoxythymidine-primed first strand 
synthesis using 2 μg of oligo(-deoxythymidine)-selected MV1 RNA as a template, an anchor 
adaptor primer was ligated to this single stranded cDNA and amplified using this primer and a 
specific primer (located at 457-481) as PCR primers (5 cycli, using 10 pmol of each primer, and 
Taq polymerase). For further PCR amplification, another specific primer was used (located at 
position 403-427). 35 cycli of amplification were performed: denaturation for 45 s. at 94 °C, 
annealing for 45 s. at 60 °C, and extension for 1.5 min. at 72 °C. Final extension was allowed to 
proceed for 7 min. PCR products were analyzed on an agarose gel, treated with T4 DNA 
polymerase to create blunt ends and cloned into a blunt-end vector. 
Transfection. Transection was performed in the BLM cell line using lipofectin (BRL, Life 
Technologies Inc..Grand Island, New York) and 20 pg of pZIPneo (16,17) carrying the G418 
resistance gene and a cDNA clone (416-2656) or the resistance gene alone. Stable transfectants 
were selected in the presence of 1 mg/ml of G418 in the culture medium. After selection, cells 
were grown in the presence of 0.5 mg/ml G418. 
In vivo assay for metastases. Approximately ЗхІО6 cells were inoculated s.c. into nude mice. 
Tumor volumes were measured weekly and mice were allowed to sit for three months unless the 
tumor size interfered with the animal's health. After autopsy, the lungs were formalin fixed and 
embedded in paraffin. Cross sections were microscopically examined for metastases. 
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RESULTS 
Isolation of differentially expressed cDNA clones. MV1 and MV3 are two human melanoma 
cell lines, derived from the same melanoma metastasis, with a low and high metastatic potential in 
nude mice respectively. In order to isolate clones specifically expressed in the high-metastatic cell 
line, a subtractive cDNA library was constructed from MV3 sequences minus MV1 sequences. To 
evaluate the enrichment of this cDNA library, 24 cDNA clones were picked at random, 
radiolabeled, and hybridized to Northern blots containing several human melanoma cell lines with 
varying metastatic potential in nude mice. 12 of 24 clones did not show differential expression. 10 
of 24 cDNA clones only showed a slightly elevated expression in the MV3 cell line. Sequencing 
of part of these clones revealed several known sequences, among which ribosomal protein L8, and 
human mitochondrial genes for several tRNAs (Phe, Val, Leu) and 12S and 16S ribosomal RNAs. 
Figure 1: Northern blot 
analysis of human melanoma 
cell lines and xenografts. As a 
molecular weight marker λ 
DNA was used restricted with 
Hindlll. nmb (top) was used 
as a probe. Lane A:1F6, 
B:530, C:M14, D:Mel57, 
E:MV1, F:MV3, and G:BLM 
RNA isolated from cell lines; 
lane H:1F6, I:M14, J:MV1, 
K:MV3, and L:BLM RNA 
isolated from xenografts. As a 
c o n t r o l a r i b o s o m a l 
hybridization is shown. 
В 
Η I К L M (kb) 
-23 
-9.4 
-6.6 
- 4 . 4 
- 2 . 3 
- 2 . 0 
28S 
rRNA 
Curiously, two cDNA clones, designated nma and nmb, showed an almost exclusive expression in 
low-metastatic cell lines. The expression of nmb is shown in Figure 1. The xenografts of a 
number of these cell lines reveal the same pattern as in the cell lines themselves: RNA expression 
is very low or absent in the high-metastatic BLM and MV3 xenografts and present in xenografts 
derived from the low-metastatic cell lines. Only after a prolonged exposure of the film, a very 
weak signal could be detected in the MV3 cell line and the BLM xenograft. 
Cloning and sequence analysis of nmb. Both nma and nmb were partially sequenced to reveal 
possible identities with already known genes. In both cases, a novel gene appeared to be involved. 
By screening an MV1 cDNA library, two nmb clones were obtained, the longer cDNA being 
2349 bp. Primer extension analysis using a 5'part of this cDNA (Avall-Ndel 149 bp fragment at 
position 331-480 of the full length clone) showed an extension product of about 330 bp; more 
bands were detected, corresponding to a missing 5'part of 299, 301, and 304 bp (not shown). The 
missing part was cloned using PCR amplification and a set of specific nested primers and showed 
products with various length, corresponding to missing parts of 301, 305 and 306 bp. Obviously, 
there is some heterogeneity at the transcription start site of the clone. The complete sequence is 
given in Figure 2. 
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IС ( ADAT ICCCAGMGMCJ 
Figure 2: Complete miclcotide sequence of nmb 
(accession number X76534 EMBL H.sapiens nmb 
RNA) and translated predicted protein. The brackets 
are used to indicate the 5'-end of the varioui PCR 
reactions. 
Sequence analysis showed no identities 
with known genes or proteins, except for a 
transcript, that was only partially 
sequenced (300 bp) and isolated from 
human heart. The highest homology at the 
protein level could be detected with the 
precursor of ρ Mel 17, a melanocyte-specifíc 
protein (overall identity after alignment of 
these two sequences was 33%; see Figure 
3). When including conserved amino acid 
changes homology went up to 56%. A 
putative signal cleavage site was located at 
position 25. Potential glycosylation and 
phosphorylation sites, and the RGD 
adhesion sequence were also detected and 
are schematically depicted in Figure 4. 
Expression of nmb in non-melanocytic 
tissue and tumors. For further 
characterization, a number of other tumors 
and tumor cell lines were screened. Within 
a panel of 23 human cell lines, including 
melanoma, fibrosarcoma, renal, cervix, 
colon, gastric, mammary and pancreas 
carcinoma, hepatoma, and myeloid 
leukemia cell lines, expression could only 
be detected in the case of U937 DK, a cell 
line derived from pleural effusion of a 
patient with diffuse histiocytic lymphoma, 
and in 3 out of 4 human renal carcinoma 
cell lines (not shown). When examining 
human smooth muscle-derived tumors and 
normal adjacent tissue, nmb expression 
could be found in smooth muscle tissue as 
well as in tumor material (expression was 
detected in 3 of 4 uteri, 2 of 3 
leiomyomas, 2 of 4 adjacent smooth 
muscle tissue samples, and 3 of 7 
leiomyosarcomas). Repeated attempts to 
demonstrate nmb expression in rat organs 
and Dunning rat prostatic tumors failed, 
under moderately stringent conditions. To 
determine whether this sequence represents 
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Figure 3: Alignment of pMell7 (В) to 
the predicted protein of nmb 
(pnmb;A). Conserved cysteines are 
shown in boxea. 
3 2 0 GPCPPPPPPPRPSKPTP 3 3 6 
3 29 TEWGTTPGQAPTAEPSGTTSVQVPTTEVISTAPVQHPTAESTGHTPEKV 3 7 8 
3 3 7 SLGPAGDNPLELSRIPDE. . .NCQINR 3 6 0 
П И | . . . | · ·•• •• '\ •• I 
4 2 9 ELPIPEPEGPDASSIHSTESITGSLGPLLDGTATLRLVXRQVPLDCVLYR 4 7 8 
3 6 1 YGHFQATITIVEGILEVNIIQMTDVmPVPWPESSLIDFWTCbGSIPTE | | | . | : . | h | | : . : : | : | | . . | : . : : : . | # I = : I • I 
4 7 9 YGSFSVTLDIVQG. . IESAEILQAVPSGEGDAFELTVSfeßGGLPKE
 5 2 2 
4 1 0 
4 1 1 
523 
'IISD: 
[ E i s s p d d 
ITQNTVlc|SPVDVDE! 
I|: · • · M I N I • 
PPAQRLÊ0PVLPSP1 
,LTVRRTF.NGSGT' 
il {••••••••• - M i l l 
LVLHQILKGGSGT' 
LTLGD 459 
H : · I : I 
.NVSLAD 572 
460 DTSIALTSTLISVPDRD. . .PASPLRMANSALISVGCLAIFVTVISLLVY 506 
..|||:.|| : :| .: ·= • = = · =11 · |.::..h- 1 = 1 
573 TMSLAWSTQLIMPVPGILLTGQEAGLGQVPLIVGILLVIJIAWLASLIY 622 
507 KKHKEYNPIENSPGNWRSKGLSVFLNRAXAVFFPGNQEKDPLLKNQEF 555 
::: . . : |...:.:|. | :|. :: . .. .|..|||..|:· 
623 RRR. .LMKQDFSVPQLPHSS. .SHWLRLPRIFCSCPIGENSPLLSGMV 667 
hydr
°
 S/'^^^^'f^^^^r~A^/\r^^^ 
Phospho 
Membrane asas— 
RGD 
N-glyco 
- C (O p - -<0—ЧС) c-t-c—c-
_âJ_ l 1 ИМ 
_u_ 
Figure 4: Characteristics of pnmb. The upper panel shows a Kytc and Doolittle prediction of hydrophilicity. Hydrophobic 
regions are indicated by negative values. Based on consensus sequences, a number of casein kinase II and protein kinase С 
phosphorylation sites were found, as indicated by С or P. Whenever there were additional requirements such as basic or 
acid residues around the consensus sequences in order to make it a biologically active substrate, sites which lacked these 
characteristics were placed between brackets. The RGD sequence is marked by an asterisk. 
Figure 5: Southern blot analysis of 10 μg of EcoRI-
digested chromosomal DNAs isolated from various 
species, λ Hindlll was used as a size marker, nmb as a 
molecular probe. Lane l:lamprey, lane 2:trout, lane 
3:Xenopus, lane 4:monitor lizard, lane 5:Peking duck, 
lane 6:pigeon, lane 7:chicken, lane 8:calf, lane 
9:hamster, lane 10:rat (tissue culture), lane llrman. 
DN CN MM1 MM2 MM3 MM4 MM5 MM6 M(kb) 
Figure 6: Northern blot analysis of human cutaneous 
- 6.6 melanocyte lesions. NN: naevi naevocellulares (9 lesions of 7 
patienta), DN: dysplastic nevi (22 lesions from 17 patients), CN: 
- 4.4 congenital nevi (6 lesions from 6 patients), MM: melanoma 
metastasis. Pigmentation was strong in MM1, weak in MM6 and 
absent in the other metastases. The molecular weight marker was 
- 2.3 XDNA that was digested with restriction enzyme Hindlll. A 
" control ribosomal hybridization is shown at the bottom. 
rRNA 
a human-specific sequence, a Southern blot containing EcoRI digested chromosomal DNAs from 
various species was screened, see Figure 5, indicating that a homologous gene is present in calf. 
Expression of nmb in human melanocytic lesions. When screening a Northern blot containing 
RNA from various patient lesions (several types of nevocellular nevi and melanoma metastases), 
nmb could be detected in all types of lesions, although expression seemed to be absent in at least 
one and low or absent in two other melanoma metastases (see Figure 6; MM2, MM3 and MM5). 
When examining a panel of 12 melanoma metastases, which we also screened with calcyclin and 
thymosin ß-10 as specific probes, expression of nmb could be detected in all lesions after a 
prolonged exposure of the film. Remarkably, those metastases which had an overexpression of 
calcyclin and/or thymosin ß-10 showed a decreased expression of nmb and were all non-
pigmented except for one lesion which showed a light pigmentation (see MM1, MM7, MM8 and 
MM9 in Figure 7 and MM2, MM3, and MM5 in Figure 6). 
Transfection of nmb into a highly metastatic cell line. Highly metastatic BLM melanoma 
cells were transfected with pZipneo which contains the neomycin resistance gene (16,17) with a 
partial nmb cDNA (416-2656) or pZipneo alone. Thirteen nmb transfectants, the parental cell line, 
and the mock-transfected parental cell line using lipofectin only, and six controls (neo 
transfectants) were examined at the RNA level for expression of nmb. All nmb-transfectants 
expressed this messenger, except for one (see Figure 8). No expression was detected in the control 
cell lines. Based on the expression of nmb as well as that of calcyclin, and thymosin ß-10, which 
we found to be progression associated (6,7,18), three transfectants (clone 21.5, 21.8, and 21.19) 
were chosen for evaluation of their growth rate and metastatic potential in nude mice. In cell 
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Figure 7: Northern blot analysis of 12 
melanoma metastases. The control 
ribosomal hybridization is shown at 
the bottom. Metastases in lane 1, 2 
and 4 correspond with MMS, MM1, 
and MM6 of Figure 6 respectively. 
Pigmentation was strong in the 
metastases in lane 2, 6, and 10-12; 
moderate in MM3 (lane 3), weak in 
those in lane 4 and 7, and absent in 
those in lane 1, 5, 8, and 9. 
calcyclin 
thymosin ß 10 
rRNA 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 M (kb) 
- · m • · · 
9.4 
6.6 
4.4 
2.3 
• · · · ·
 с а І С
У
С І І п 
thymosin ßlO 
28S rRNA 
Figure 8: Northern blot analysis of BLM-nmb transfectants. λ Hindlll was used as a moleclar marker. Expression of 
calcyclin and thymosin ß-10, and a control hybridization are shown at the bottom (28S rRNA). Lane 1: 21.1, lane 2:21.2, 
lane 3:21.5, lane 4:21.8, lane 5:21.7, lane 6: 21.12, lane 7:21.14, lane 8:21.15, lane 9:21.16, lane 10:21.17, lane 
11:21.18, lane 12:21.19, lane 13:21.20, lane 14:BLM treated with lipofectin, lane 15: BLM, lane 16:neol, lane 17:neo7, 
lane 18:ncol0, lane 19:neol6, lane 20:neol9, lane 21:neo21. Lanes 1-13 contain nmb-transfectants, lanes 14,15 contain 
parental cell lines (BLM and mock-transfected BLM), and lanes 16-21 contain neomycin transfected controls. 
Table 1: Rates of spontaneous lung metastasis after s.c. inoculation of neomycin-, nmb-
transfectants, or parental controls in nude mice. 
C e l l L i n e A (%) В (%) 
parental BLH 
neo 1 
neo 7 
neo 16 
21.5 
21.В 
21.19 
4/5 
2/5 
N.D. 
N.D. 
l/S 
1/5 
1/4 
(80) 
(40) 
(20) 
(20) 
(25) 
5/9 
5/9 
Β/10 
5/10 
2/7 
6/10 
6/8 
(55) 
(55) 
(ВО) 
(50) 
(29) 
(60) 
(75) 
The parental cell line was mock-tranafected with 
hpofectin without adding DNA A and В represent 
separately performed experiments 
culture, differences with neomycin resistent and parental control cell lines were readily observed. 
In particular, clone 21.5 had a tendency to cluster at lower densities (see Figure 9). Growth rates 
in vitro were comparable. Upon inoculation in nude mice tumor growth was delayed in the case of 
clone 21.5, and to a lesser extent of clone 21.19 (Figure 10). After autopsy, the lungs were 
microscopically examined for metastases. Metastatic potential was reduced in 21.5 transfectants 
when compared to either parental or neomycin resistent control transfectant cell lines (Table 1). 
DISCUSSION 
Upon comparison of the expression in high- and low- metastatic cell lines, several cDNAs were 
isolated showing a differential expression in the low- and high-metastatic human melanoma cell 
lines and derived xenograft lesions. cDNA clones that showed a difference in expression of only 
2-4 fold appeared to be related to growth and metabolism. Ribosomal cDNAs were also isolated 
from a tumor-enriched colon subtraction library, in which expression was detected in both well 
and poorly differentiated cells. Increased expression correlated with progression in two pairs of 
cell lines derived from primary and metastatic lesions from the same patient (19). Although the 
aim of this subtraction library was to enrich for sequences highly expressed in the highly 
metastatic cell line, two cDNAs were isolated that showed the opposite pattern of what was 
expected. Since an excess of MV1 sequences was used to hybridize to MV3 sequences and 
labeling of MV1 sequences by photobiotinylation, hybridization, and separation of hybridized and 
non-hybridized cDNAs will not necessarily have been complete, this subtraction library will 
consequently also contain cDNAs highly expressed in the low-metastatic MV1 cell line. 
Sequence analysis of nmb, which showed expression only in the low-metastatic human 
melanoma cell lines and xenografts, revealed that this clone represents a novel gene. Based on the 
presence of a signal sequence, a hydrophobic area of 27 amino acid residues bordered by charged 
residues which might cross the membrane in a single helical span, and the prediction of integral 
membrane proteins by membrane propensity programs, we assume that this clone is encoding a 
transmembrane glycoprotein. Moreover, the nmb protein is homologous to the precursor of 
pMell7 melanocytic-specifíc protein (20) which also shows a transmembrane domain in this 
region. Since Mel 17 was described as a member of a family to which also gp75 and tyrosinase 
belong, which are both prominently expressed in melanocyte lesions, we also aligned our clone to 
these sequences and five regions of homology were detected (Figure 11). Overall identity and 
homology was 17.6 and 41.7% in the case of gp75, and 16.7 and 40.8% in the case of tyrosinase. 
All are characterized by a short noncoding region at the 5'-end of the messenger, a signal peptide, 
and a transmembrane domain near the З'-end. Nearly all cysteines are conserved between 
tyrosinase and gp75 (21), whereas all cysteines in the region preceding the transmembrane region 
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are conserved between pMell7 and pnmb (see Figure 3). Although these four proteins clearly 
belong to one family, gp75 and tyrosinase are more similar to each other than to pMell7 or 
pnmb, and vice versa. Tyrosinase is a key enzyme in the synthesis of melanin pigment and as 
such is often lost during progression into less differentiated melanoma cells. Although tyrosinase, 
gp75 and pMell7 are described to be melanocyte-specific, and tyrosinase and gp75 are localized 
in the melanosomes, nmb is expressed in other tissues and tumor cell lines as well. Therefore, it 
cannot, or not exclusively, be present in the melanosomes. 
Screening of several other cell lines, rat organs, and tumors indicated that the nmb gene has a 
restricted expression pattern, is not specific for the melanocyte lineage, and, secondly, is not well 
conserved during evolution of vertebrates. 
Although nmb RNA expression is not significantly higher in pooled specimen of nevocellular 
nevi than in melanoma metastases, no final conclusions can be drawn about its potential as a 
protein marker for particular stages in melanocytic progression, since RNA levels do not 
necessarily predict protein data. At least, in earlier studies we found that elevated RNA expression 
of calcyclin in melanoma metastases did not correlate with staining with anti-calcyclin antibodies 
(6,18). 
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Figure 10: Growth curves of the tumor· from parental, neomycin- and nmb-trensfected cell linea in nude mice. Values are 
given BE a mean of all animala tested. The values were baaed on 5 animala per cell line except for 21.19 (4 animals) in Д, 
and 10(21.8, neol, ncolo), 9(21.19, BLM, neo7) or 7 animals in the case of 21.5 in B. 
Figure 11: Multiple augment of tyrosinase, gp75, pMcll7 and pnmb. Positions were based on mature peptides. The 
regions shown were part of the alignments of the complete sequence«, as performed by using PILEUP or CLUSTALV 
alignment methode. 
Since the most important step in tumor progression is the acquisition of the metastatic 
phenotype we were interested whether nmb could reduce the metastatic potential of a highly 
metastatic nmb-negative melanoma cell line. Based on their expression pattern of nmb, calcyclin, 
and thymosin ß-10, three nmb transfectants (21.5, 21.8, and 21.19) were chosen for further 
characterization. Calcyclin levels varied in the transfectants, which was no surprise to us, since 
other experiments using various melanoma cell lines showed that endogenous calcyclin mRNA 
levels varied widely after transfection experiments or changes within the cell lines themselves 
(unpublished observations). In a preliminary series of experiments, a tendency toward growth 
delay and reduction of metastatic potential is clearly present in the case of transfectant 21.5. The 
other transfectants tested, 21.8 and 21.19 show varying levels of metastasis rates, possibly due to 
differences at the protein level. One has to note that a partial cDNA was transfected lacking the 
signal peptide. Nevertheless, since the cytoplasmic part of the peptide was present in the 
transfectants, these observations are probably meaningful and will be extended in further studies. 
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SUMMARY 
Human cutaneous melanocyte tumor progression evolves through several stages from benign 
nevocellular nevi into highly invasive and metastatic lesions. Whereas a thin primary melanoma 
(early) can be cured by surgical excision, prospects are far worse for a thick primary melanoma 
(late). One of the crucial steps is the transition of the radial growth phase of a thin primary 
melanoma into the vertical growth phase of this melanoma, since a melanoma in the radial growth 
phase seems incapable of metastasis. Until now, the most reliable parameters for prediction of the 
disease are the tumor thickness measured according to Breslow, and the Clark level of invasion. 
In order to identify new potential progression markers for human cutaneous melanoma, the 
approach of differential and subtractive hybridization cloning has been applied to two model 
systems for this progression. Two parts of a primary melanoma representing subsequent stages of 
this progression were separately transplanted into nude mice. The resulting xenografts were used 
for a differential hybridization assay. In Chapter 2, several clones isolated this way are described, 
one of which appeared to be coding for calcyclin, a small calcium-binding protein. Calcyclin 
expression was highest in highly-metastatic human melanoma cell lines, both at the RNA and 
protein level. To evaluate its value as a progression marker, a large series of patient lesions was 
screened with a polyclonal anti-calcyclin antibody as described in Chapter 3. Although no 
correlation could be detected between RNA and protein levels, calcyclin expression appeared to be 
higher in a higher percentage of melanocyte cells within a lesion in thick primary melanomas as 
compared to thin primary melanomas. This partem is also observed when dividing all primary 
melanomas into Clark levels; Clark II melanomas show a significant lower percentage of positive 
cells than melanomas with a higher Clark level, concomitant with the transition of the radial 
growth phase into the vertical growth phase. The precursor lesion of a primary melanoma, 
dysplastic nevi did not show any expression at all. As such, calcyclin can be considered a 
progression marker. However, expression was more complex and also present in the dermal part 
of normal nevi. 
For the isolation of more differentially expressed clones, a subtraction hybridization cDNA 
library was constructed using two human melanoma cell lines, which differed in their metastatic 
behavior in nude mice and were derived from the same melanoma metastasis. In Chapter 4, this 
library was differentially screened, resulting in the isolation of thymosin ßlO as a potential new 
progression marker. This was confirmed by a higher expression of thymosin BIO RNA in 
melanoma metastases than in several types of nevocellular nevi. 
In the course of screening this library, two clones were isolated, nma and nmb, which showed a 
high expression in the low-metastatic melanoma cell lines and derived xenografts, and a low 
expression or none at all in the highly metastatic cell lines and xenografts. Both clones represent 
novel genes. Further characterization of nmb is given in Chapter 5, indicating that the predicted 
protein belongs to a family of tyrosinase-related proteins. Transfection of a partial nmb clone into 
the highly metastatic BLM cell line, resulted in slower tumor growth and reduction of metastatic 
potential in nude mice in one of the transfectants. 
The predictive value of most of the clones described in this thesis, still remains to be assessed. 
Irrelevant of the outcome as a potential clinical marker, these clones will be interesting since they 
may play a role in the process of progression itself, as illustrated by the reduction of metastatic 
potential of an nmb transfectant in Chapter S. Genes that show an increased expression during 
progression often are also expressed in the benign stages, although to a lesser extent. This seems 
logical since these molecules can be involved in important physiological processes and as such are 
also necessary in normal tissue. Discrimination of benign and malignant stages may be expected 
only, if a panel of such markers is used. 
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SAMENVATTING 
De progressie van humane huidmelanomen verloopt via een aantal stadia, van onschuldige 
moedervlekken naar sterk invasieve en uitzaaiende lestes. Een vroeg primair melanoom kan geheel 
worden genezen door een chirurgische ingreep. Echter, de vooruitzichten voor een dik melanoom 
zijn een stuk slechter. Een van de cruciale stappen in deze progressie is de overgang van een 
primair melanoom in de radiale groeifase (dun) naar de verticale groeifase, aangezien in deze 
laatste fase ook het vermogen tot metastasering onstaat. Tot nu toe zijn de meest betrouwbare 
voorspellende parameters de Breslow dikte en het Clark stadium van invasie. 
Om meer progressiemerkers te vinden voor het humane huidmelanoom, zijn de methodes van 
differentiële en subtractiehybridisatie toegepast op een tweetal modelsystemen. Twee delen van 
hetzelfde melanoom, die als representief zijn gezien voor opeenvolgende stappen in de progressie 
van het huidmelanoom, werden apart in naakte muizen getransplanteerd. De daaruit voortgekomen 
tumortransplantaten werden als uitgangsmateriaal gebruikt voor een differentiële screening. In 
hoofdstuk 2 staan een aantal geïsoleerde klonen beschreven, waarvan pMWl, dat codeert voor een 
klein calcium-bindend eiwit, te weten calcycline, de meest interessante was. Om de waarde van 
deze kloon in te schatten, is een serie van humane melanocytaire lesies onderzocht op expressie 
van calcycline met behulp van een polyclonal antiserum, zoals beschreven in hoofdstuk 3. 
Alhoewel er geen correlatie bleek te zijn tussen het expressieniveau van het calcycline RNA en het 
eiwit, werd een hoger percentage van positieve melanocytaire cellen en een sterkere kleuring 
aangetroffen in dikke melanomen dan in dunne melanomen. Ook na indeling van alle melanomen 
in Clark stadia, bleek deze tendens er te zijn. Primaire melanomen in Clark stadium II toonden 
een significant lager percentage positieve melanocytaire cellen dan melanomen in een later 
stadium, wat samenvalt met de overgang van de radiale groeifase in de verticale groeifase. De 
voorlopers van het melanoom, dysplastische nevi, vertoonden in het geheel geen expressie van 
calcycline. Als zodanig kan calcycline gezien worden als een progressiemerker. Echter, calcycline 
expressie was ook aanwezig in het dermale gedeelte van moedervlekken. 
Om meer progressiemerkers op te sporen werd een subtractie cDNA bank gemaakt van twee 
humane melanoma cellijnen, die van elkaar verschilden in hun metastaserend vermogen in naakte 
muizen en waren gemaakt uitgaande van dezelfde métastase. In hoofdstuk 4 wordt de differentiële 
screening van deze bank beschreven, hetgeen leidde tot de identificatie van thymosine BIO als een 
mogelijke nieuwe progressiemerker. Dit werd bevestigd door een hogere thymosine BIO RNA 
expressie in melanoom metastasen in verhouding tot een aantal typen nevocellulaire nevi. 
Tijdens de karakterisering van deze bank werd ook een tweetal klonen geïsoleerd, nma en nmb, 
die een hoge expressie hadden in de laag metastaserende cellijnen en afgeleide tumortransplantaten 
en een lage expressie of helemaal geen expressie in de hoog metastaserende varianten. Zoals 
beschreven in hoofdstuk 5, blijken deze klonen van nog niet beschreven genen afkomstig te zijn. 
Het voorspelde eiwit van nmb behoort tot een familie waartoe ook tyrosinase behoort. Transfectie 
van een gedeelte van deze kloon in een hoog metastaserende melanoom cellijn, BLM, leidde tot 
langzamere tumorgroei en een afname van het metastaserend vermogen in naakte muizen in één 
van de nmb-transfectanten. 
De klinische toepasbaarheid van de meeste klonen, die in dit proefschrift staan beschreven, 
moet nog worden vastgesteld. Ongeacht de uitkomst, kunnen deze klonen toch interessant zijn, 
omdat zij mogelijk een rol spelen in deze tumorprogressie, zoals wordt geïllustreerd in hoofdstuk 
5, waarin transfectie van een gedeelte van nmb leidt tot een reductie in het metastaserend 
vermogen in naakte muizen. Genen, die een verhoogde expressie te zien geven in hoog 
metastaserende cellijnen en tumortransplantaten vertonen ook vaak een expressie in laag 
metastaserende lijnen, zij het dan op een veel lager niveau. Aangezien deze moleculen een rol 
kunnen spelen in belangrijke fysiologische processen, is expressie uiteraard ook nodig in normaal 
weefsel. Onderscheid tussen de verschillende stadia zal dan ook pas bereikt kunnen worden indien 
een serie van deze markers wordt toegepast. 
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